Page last updated: 2024-08-01 23:20:21
dolichols
Description
Dolichols: A class of polyprenols which contain approximately 20 isoprene residues. Although considered ISOPRENOIDS, they terminate with an alpha-saturated isoprenoid group at the hydroxy end of the molecule. [MeSH]
Dolichol-20 : no description available [CHeBI]
Cross-References
Synonyms (9)
| Synonym |
|---|
| dolichol-20 |
| dolichol 20 |
| dolichols |
| (6e,10e,14e,18e,22z,26e,30e,34e,38e,42e,46e,50e,54e,58z,62e,66e,70e,74e)-3,7,11,15,19,23,27,31,35,39,43,47,51,55,59,63,67,71,75,79-icosamethyloctaconta-6,10,14,18,22,26,30,34,38,42,46,50,54,58,62,66,70,74,78-nonadecaen-1-ol |
| dolichol (c100) |
| 2067-66-5 |
| 6,10,14,18,22,26,30,34,38,42,46,50,54,58,62,66,70,74,78-octacontanonadecaen-1-ol, 3,7,11,15,19,23,27,31,35,39,43,47,51,55,59,63,67,71,75,79-eicosamethyl- |
| CHEBI:88766 |
| Q418203 |
Drug Classes (1)
| Class | Description |
|---|
| polyterpene | A C5n terpene, where n is greater than 8. |
Pathways (2)
dolichols is involved in 2 pathway(s), involving a total of 15 unique proteins and 45 unique compounds
Research
Studies (738)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|
| pre-1990 | 318 (43.09) | 18.7374 |
| 1990's | 191 (25.88) | 18.2507 |
| 2000's | 149 (20.19) | 29.6817 |
| 2010's | 64 (8.67) | 24.3611 |
| 2020's | 16 (2.17) | 2.80 |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|
| Trials | 13 (1.70%) | 5.53% |
| Reviews | 70 (9.16%) | 6.00% |
| Case Studies | 10 (1.31%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 671 (87.83%) | 84.16% |
| Substance | Studies | Classes | Roles | First Year | Last Year | Average Age | Relationship Strength | Trials | pre-1990 | 1990's | 2000's | 2010's | post-2020 |
|---|
| ethylene dichloride | | chloroethanes | hepatotoxic agent;
mutagen;
non-polar solvent | 1995 | 2002 | 25.0 | low | 0 | 0 | 2 | 1 | 0 | 0 |
| gamma-aminobutyric acid | | amino acid zwitterion;
gamma-amino acid;
monocarboxylic acid | human metabolite;
neurotransmitter;
Saccharomyces cerevisiae metabolite;
signalling molecule | 1989 | 1989 | 35.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
| acetic acid | | monocarboxylic acid | antimicrobial food preservative;
Daphnia magna metabolite;
food acidity regulator;
protic solvent | 1982 | 1988 | 39.9 | low | 0 | 7 | 0 | 0 | 0 | 0 |
| adenine | | 6-aminopurines;
purine nucleobase | Daphnia magna metabolite;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite | 1981 | 1985 | 41.0 | low | 0 | 2 | 0 | 0 | 0 | 0 |
| choline | | cholines | allergen;
Daphnia magna metabolite;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
neurotransmitter;
nutrient;
plant metabolite;
Saccharomyces cerevisiae metabolite | 2000 | 2000 | 24.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| citric acid, anhydrous | | tricarboxylic acid | antimicrobial agent;
chelator;
food acidity regulator;
fundamental metabolite | 2018 | 2018 | 6.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| fosmidomycin | | hydroxamic acid;
phosphonic acids | antimicrobial agent;
bacterial metabolite;
EC 1.1.1.267 (1-deoxy-D-xylulose-5-phosphate reductoisomerase) inhibitor | 2004 | 2004 | 20.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| dimethyl sulfoxide | | sulfoxide;
volatile organic compound | alkylating agent;
antidote;
Escherichia coli metabolite;
geroprotector;
MRI contrast agent;
non-narcotic analgesic;
polar aprotic solvent;
radical scavenger | 1976 | 1976 | 48.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
| ethanolamine | | ethanolamines;
primary alcohol;
primary amine | Escherichia coli metabolite;
human metabolite;
mouse metabolite | 1988 | 1988 | 36.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
| methanol | | alkyl alcohol;
one-carbon compound;
primary alcohol;
volatile organic compound | amphiprotic solvent;
Escherichia coli metabolite;
fuel;
human metabolite;
mouse metabolite;
Mycoplasma genitalium metabolite | 1989 | 2007 | 26.0 | low | 0 | 1 | 0 | 1 | 0 | 0 |
| orotic acid | | pyrimidinemonocarboxylic acid | Escherichia coli metabolite;
metabolite;
mouse metabolite | 1983 | 1998 | 33.5 | low | 0 | 1 | 1 | 0 | 0 | 0 |
| palmitic acid | | long-chain fatty acid;
straight-chain saturated fatty acid | algal metabolite;
Daphnia magna metabolite;
EC 1.1.1.189 (prostaglandin-E2 9-reductase) inhibitor;
plant metabolite | 1988 | 1996 | 32.0 | low | 0 | 1 | 2 | 0 | 0 | 0 |
| phthalic acid | | benzenedicarboxylic acid | human xenobiotic metabolite | 1987 | 1987 | 37.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
| purine | | purine | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| pyridoxal phosphate | | methylpyridines;
monohydroxypyridine;
pyridinecarbaldehyde;
vitamin B6 phosphate | coenzyme;
cofactor;
EC 2.7.7.7 (DNA-directed DNA polymerase) inhibitor;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite | 2004 | 2004 | 20.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| pyridoxine 5-phosphate | | vitamin B6 phosphate | Escherichia coli metabolite;
mouse metabolite | 2004 | 2004 | 20.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| quinolinic acid | | pyridinedicarboxylic acid | Escherichia coli metabolite;
human metabolite;
mouse metabolite;
NMDA receptor agonist | 2003 | 2003 | 21.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| urea | | isourea;
monocarboxylic acid amide;
one-carbon compound | Daphnia magna metabolite;
Escherichia coli metabolite;
fertilizer;
flour treatment agent;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| isopentenyl pyrophosphate | | prenol phosphate | antigen;
antioxidant;
epitope;
Escherichia coli metabolite;
mouse metabolite;
phosphoantigen | 1991 | 2016 | 25.0 | low | 0 | 0 | 3 | 0 | 1 | 0 |
| perillic acid | | alpha,beta-unsaturated monocarboxylic acid;
cyclohexenecarboxylic acid | antineoplastic agent;
human metabolite;
mouse metabolite | 1995 | 1995 | 29.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| 1-anilino-8-naphthalenesulfonate | | aminonaphthalene;
naphthalenesulfonic acid | fluorescent probe | 1993 | 1997 | 29.0 | low | 0 | 0 | 2 | 0 | 0 | 0 |
| amitrole | | aromatic amine;
triazoles | carotenoid biosynthesis inhibitor;
EC 1.11.1.6 (catalase) inhibitor;
herbicide | 1996 | 1996 | 28.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| 3-methylcholanthrene | | ortho- and peri-fused polycyclic arene | aryl hydrocarbon receptor agonist;
carcinogenic agent | 1987 | 1990 | 35.5 | low | 0 | 1 | 1 | 0 | 0 | 0 |
| aspirin | | benzoic acids;
phenyl acetates;
salicylates | anticoagulant;
antipyretic;
cyclooxygenase 1 inhibitor;
cyclooxygenase 2 inhibitor;
drug allergen;
EC 1.1.1.188 (prostaglandin-F synthase) inhibitor;
geroprotector;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
plant activator;
platelet aggregation inhibitor;
prostaglandin antagonist;
teratogenic agent | 1991 | 1996 | 30.5 | low | 0 | 0 | 2 | 0 | 0 | 0 |
| chloroquine | | aminoquinoline;
organochlorine compound;
secondary amino compound;
tertiary amino compound | anticoronaviral agent;
antimalarial;
antirheumatic drug;
autophagy inhibitor;
dermatologic drug | 1986 | 1986 | 38.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
| clofibrate | | aromatic ether;
ethyl ester;
monochlorobenzenes | anticholesteremic drug;
antilipemic drug;
geroprotector;
PPARalpha agonist | 1987 | 2003 | 31.3 | low | 0 | 2 | 4 | 1 | 0 | 0 |
| clofibric acid | | aromatic ether;
monocarboxylic acid;
monochlorobenzenes | anticholesteremic drug;
antilipemic drug;
antineoplastic agent;
herbicide;
marine xenobiotic metabolite;
PPARalpha agonist | 2000 | 2000 | 24.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| erythrosine | | | | 1987 | 1987 | 37.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
| ether | | ether;
volatile organic compound | inhalation anaesthetic;
non-polar solvent;
refrigerant | 1987 | 1987 | 37.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
| gemfibrozil | | aromatic ether | antilipemic drug | 1992 | 2003 | 25.7 | low | 0 | 0 | 2 | 1 | 0 | 0 |
| gentamicin | | | | 1991 | 1991 | 33.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| 2-propanol | | secondary alcohol;
secondary fatty alcohol | protic solvent | 2003 | 2003 | 21.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| isoproterenol | | catechols;
secondary alcohol;
secondary amino compound | beta-adrenergic agonist;
bronchodilator agent;
cardiotonic drug;
sympathomimetic agent | 2003 | 2003 | 21.0 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| meclofenoxate | | monocarboxylic acid | | 1990 | 1990 | 34.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| muscimol | | alkaloid;
isoxazoles;
primary amino compound | fungal metabolite;
GABA agonist;
oneirogen;
psychotropic drug | 1989 | 1989 | 35.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
| phenobarbital | | barbiturates | anticonvulsant;
drug allergen;
excitatory amino acid antagonist;
sedative | 1982 | 1994 | 36.6 | low | 0 | 5 | 2 | 0 | 0 | 0 |
| probucol | | dithioketal;
polyphenol | anti-inflammatory drug;
anticholesteremic drug;
antilipemic drug;
antioxidant;
cardiovascular drug | 1994 | 1994 | 30.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| sulfobromophthalein | | 2-benzofurans;
organobromine compound;
organosulfonic acid;
phenols | dye | 1989 | 1989 | 35.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
| trifluoperazine | | N-alkylpiperazine;
N-methylpiperazine;
organofluorine compound;
phenothiazines | antiemetic;
calmodulin antagonist;
dopaminergic antagonist;
EC 1.8.1.12 (trypanothione-disulfide reductase) inhibitor;
EC 5.3.3.5 (cholestenol Delta-isomerase) inhibitor;
phenothiazine antipsychotic drug | 1986 | 1986 | 38.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
| sorbitol | | glucitol | cathartic;
Escherichia coli metabolite;
food humectant;
human metabolite;
laxative;
metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite;
sweetening agent | 2017 | 2017 | 7.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| thymidine | | pyrimidine 2'-deoxyribonucleoside | Escherichia coli metabolite;
human metabolite;
metabolite;
mouse metabolite | 1990 | 1990 | 34.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| thyroxine | | 2-halophenol;
iodophenol;
L-phenylalanine derivative;
non-proteinogenic L-alpha-amino acid;
thyroxine zwitterion;
thyroxine | antithyroid drug;
human metabolite;
mouse metabolite;
thyroid hormone | 1996 | 1996 | 28.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| estrone | | 17-oxo steroid;
3-hydroxy steroid;
phenolic steroid;
phenols | antineoplastic agent;
bone density conservation agent;
estrogen;
human metabolite;
mouse metabolite | 1978 | 1978 | 46.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
| dehydroepiandrosterone | | 17-oxo steroid;
3beta-hydroxy-Delta(5)-steroid;
androstanoid | androgen;
human metabolite;
mouse metabolite | 1996 | 1996 | 28.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| 2-acetylaminofluorene | | 2-acetamidofluorenes | antimitotic;
carcinogenic agent;
epitope;
mutagen | 1984 | 1995 | 35.3 | low | 0 | 2 | 1 | 0 | 0 | 0 |
| diethylnitrosamine | | nitrosamine | carcinogenic agent;
hepatotoxic agent;
mutagen | 1983 | 1990 | 37.3 | low | 0 | 2 | 1 | 0 | 0 | 0 |
| methyldimethylaminoazobenzene | | | | 1987 | 1987 | 37.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
| carbon tetrachloride | | chlorocarbon;
chloromethanes | hepatotoxic agent;
refrigerant | 2000 | 2003 | 22.7 | low | 0 | 0 | 1 | 2 | 0 | 0 |
| lysine | | aspartate family amino acid;
L-alpha-amino acid zwitterion;
L-alpha-amino acid;
lysine;
organic molecular entity;
proteinogenic amino acid | algal metabolite;
anticonvulsant;
Escherichia coli metabolite;
human metabolite;
micronutrient;
mouse metabolite;
nutraceutical;
plant metabolite;
Saccharomyces cerevisiae metabolite | 2004 | 2004 | 20.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| sucrose | | glycosyl glycoside | algal metabolite;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
osmolyte;
Saccharomyces cerevisiae metabolite;
sweetening agent | 1993 | 1993 | 31.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| uridine monophosphate | | pyrimidine ribonucleoside 5'-monophosphate;
uridine 5'-phosphate | Escherichia coli metabolite;
human metabolite;
mouse metabolite | 1978 | 1999 | 35.5 | low | 0 | 1 | 1 | 0 | 0 | 0 |
| uridine diphosphate | | pyrimidine ribonucleoside 5'-diphosphate;
uridine 5'-phosphate | Escherichia coli metabolite;
mouse metabolite | 1978 | 1978 | 46.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
| galactose | | D-galactose;
galactopyranose | Escherichia coli metabolite;
mouse metabolite | 1975 | 1991 | 39.6 | low | 0 | 4 | 1 | 0 | 0 | 0 |
| edetic acid | | ethylenediamine derivative;
polyamino carboxylic acid;
tetracarboxylic acid | anticoagulant;
antidote;
chelator;
copper chelator;
geroprotector | 1975 | 1977 | 47.8 | low | 0 | 4 | 0 | 0 | 0 | 0 |
| tyrosine | | amino acid zwitterion;
erythrose 4-phosphate/phosphoenolpyruvate family amino acid;
L-alpha-amino acid;
proteinogenic amino acid;
tyrosine | EC 1.3.1.43 (arogenate dehydrogenase) inhibitor;
fundamental metabolite;
micronutrient;
nutraceutical | 1990 | 2013 | 21.3 | low | 4 | 0 | 1 | 14 | 1 | 0 |
| adenosine monophosphate | | adenosine 5'-phosphate;
purine ribonucleoside 5'-monophosphate | adenosine A1 receptor agonist;
cofactor;
EC 3.1.3.1 (alkaline phosphatase) inhibitor;
EC 3.1.3.11 (fructose-bisphosphatase) inhibitor;
fundamental metabolite;
micronutrient;
nutraceutical | 1975 | 1977 | 48.0 | low | 0 | 2 | 0 | 0 | 0 | 0 |
| leucine | | amino acid zwitterion;
L-alpha-amino acid;
leucine;
proteinogenic amino acid;
pyruvate family amino acid | algal metabolite;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
plant metabolite;
Saccharomyces cerevisiae metabolite | 1982 | 2007 | 33.0 | low | 0 | 4 | 1 | 1 | 0 | 0 |
| cytidine diphosphate | | cytidine 5'-phosphate;
pyrimidine ribonucleoside 5'-diphosphate | Escherichia coli metabolite;
mouse metabolite | 1989 | 1989 | 35.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
| uridine triphosphate | | pyrimidine ribonucleoside 5'-triphosphate;
uridine 5'-phosphate | Escherichia coli metabolite;
mouse metabolite | 1986 | 1986 | 38.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
| methionine | | aspartate family amino acid;
L-alpha-amino acid;
methionine zwitterion;
methionine;
proteinogenic amino acid | antidote to paracetamol poisoning;
human metabolite;
micronutrient;
mouse metabolite;
nutraceutical | 1997 | 2002 | 24.5 | low | 0 | 0 | 1 | 1 | 0 | 0 |
| cytidine triphosphate | | cytidine 5'-phosphate;
pyrimidine ribonucleoside 5'-triphosphate | Escherichia coli metabolite;
mouse metabolite | 1978 | 2010 | 34.2 | low | 0 | 6 | 0 | 2 | 0 | 0 |
| cycloheximide | | antibiotic fungicide;
cyclic ketone;
dicarboximide;
piperidine antibiotic;
piperidones;
secondary alcohol | anticoronaviral agent;
bacterial metabolite;
ferroptosis inhibitor;
neuroprotective agent;
protein synthesis inhibitor | 1985 | 2002 | 31.8 | low | 0 | 3 | 2 | 1 | 0 | 0 |
| egtazic acid | | diether;
tertiary amino compound;
tetracarboxylic acid | chelator | 1986 | 1986 | 38.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
| asparagine | | amino acid zwitterion;
asparagine;
aspartate family amino acid;
L-alpha-amino acid;
proteinogenic amino acid | Escherichia coli metabolite;
human metabolite;
micronutrient;
mouse metabolite;
nutraceutical;
plant metabolite;
Saccharomyces cerevisiae metabolite | 1981 | 2013 | 29.6 | low | 0 | 3 | 3 | 2 | 1 | 0 |
| n-pentanol | | pentanol;
short-chain primary fatty alcohol | human metabolite;
plant metabolite | 1987 | 2018 | 20.6 | low | 0 | 1 | 2 | 5 | 2 | 0 |
| valine | | L-alpha-amino acid zwitterion;
L-alpha-amino acid;
proteinogenic amino acid;
pyruvate family amino acid;
valine | algal metabolite;
Escherichia coli metabolite;
human metabolite;
micronutrient;
mouse metabolite;
nutraceutical;
Saccharomyces cerevisiae metabolite | 1998 | 1998 | 26.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| threonine | | amino acid zwitterion;
aspartate family amino acid;
L-alpha-amino acid;
proteinogenic amino acid;
threonine | algal metabolite;
Escherichia coli metabolite;
human metabolite;
micronutrient;
mouse metabolite;
nutraceutical;
plant metabolite;
Saccharomyces cerevisiae metabolite | 1976 | 1976 | 48.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
| tryptophan | | erythrose 4-phosphate/phosphoenolpyruvate family amino acid;
L-alpha-amino acid zwitterion;
L-alpha-amino acid;
proteinogenic amino acid;
tryptophan zwitterion;
tryptophan | antidepressant;
Escherichia coli metabolite;
human metabolite;
micronutrient;
mouse metabolite;
nutraceutical;
plant metabolite;
Saccharomyces cerevisiae metabolite | 2002 | 2008 | 20.8 | low | 3 | 0 | 0 | 15 | 0 | 0 |
| arginine | | arginine;
glutamine family amino acid;
L-alpha-amino acid;
proteinogenic amino acid | biomarker;
Escherichia coli metabolite;
micronutrient;
mouse metabolite;
nutraceutical | 2004 | 2004 | 20.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| ethane | | alkane;
gas molecular entity | plant metabolite;
refrigerant | 1998 | 1998 | 26.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| tert-butylhydroperoxide | | alkyl hydroperoxide | antibacterial agent;
oxidising agent | 1994 | 1994 | 30.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| isoprene | | alkadiene;
hemiterpene;
volatile organic compound | plant metabolite | 1987 | 2016 | 22.1 | low | 0 | 1 | 3 | 2 | 2 | 0 |
| isoprene | | alkadiene;
hemiterpene;
volatile organic compound | plant metabolite | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| 1,1,2,2-tetrachloroethane | | chloroethanes | | 1998 | 1998 | 26.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| taurocholic acid | | amino sulfonic acid;
bile acid taurine conjugate | human metabolite | 1977 | 1982 | 44.5 | low | 0 | 2 | 0 | 0 | 0 | 0 |
| phenylhydrazine | | phenylhydrazines | xenobiotic | 1982 | 2003 | 28.7 | low | 0 | 1 | 0 | 2 | 0 | 0 |
| 2-methylpentane | | alkane | | 2007 | 2007 | 17.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| pentane | | alkane;
volatile organic compound | non-polar solvent;
refrigerant | 1987 | 2015 | 25.2 | low | 0 | 1 | 5 | 2 | 1 | 0 |
| thiophenes | | mancude organic heteromonocyclic parent;
monocyclic heteroarene;
thiophenes;
volatile organic compound | non-polar solvent | 1992 | 1992 | 32.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| diethylhexyl phthalate | | diester;
phthalate ester | androstane receptor agonist;
apoptosis inhibitor;
plasticiser | 1983 | 2000 | 32.7 | low | 0 | 4 | 6 | 0 | 0 | 0 |
| uridine diphosphate glucose | | UDP-D-glucose | fundamental metabolite | 1974 | 1981 | 46.7 | low | 0 | 12 | 0 | 0 | 0 | 0 |
| 2-ethylhexanoic acid | | branched-chain fatty acid | | 1996 | 1996 | 28.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| hexanoic acid | | medium-chain fatty acid;
straight-chain saturated fatty acid | human metabolite;
plant metabolite | 1998 | 1998 | 26.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| pyrimidine | | diazine;
pyrimidines | Daphnia magna metabolite | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| pyrazines | | diazine;
pyrazines | Daphnia magna metabolite | 2004 | 2004 | 20.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| methylthioinosine | | purine ribonucleoside;
thiopurine | | 1987 | 1987 | 37.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
| trans-1,4-bis(2-chlorobenzaminomethyl)cyclohexane dihydrochloride | | | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| uridine diphosphate n-acetylglucosamine | | | | 1975 | 1999 | 45.1 | low | 0 | 11 | 1 | 0 | 0 | 0 |
| perillyl alcohol | | limonene monoterpenoid | plant metabolite;
volatile oil component | 1995 | 1995 | 29.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| malondialdehyde | | dialdehyde | biomarker | 2007 | 2007 | 17.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| beta-phellandrene | | phellandrene | plant metabolite | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| prenol | | alkenyl alcohol;
prenols | | 1987 | 2018 | 21.6 | medium | 0 | 1 | 2 | 5 | 1 | 0 |
| acetylcysteine | | acetylcysteine;
L-cysteine derivative;
N-acetyl-L-amino acid | antidote to paracetamol poisoning;
antiinfective agent;
antioxidant;
antiviral drug;
ferroptosis inhibitor;
geroprotector;
human metabolite;
mucolytic;
radical scavenger;
vulnerary | 1995 | 1995 | 29.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| d-alpha tocopherol | | alpha-tocopherol | algal metabolite;
antiatherogenic agent;
anticoagulant;
antioxidant;
antiviral agent;
EC 2.7.11.13 (protein kinase C) inhibitor;
immunomodulator;
micronutrient;
nutraceutical;
plant metabolite | 1982 | 2007 | 29.3 | low | 0 | 3 | 4 | 3 | 0 | 0 |
| fucose | | fucopyranose;
L-fucose | Escherichia coli metabolite;
mouse metabolite | 1990 | 1990 | 34.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| uridine diphosphate galactose | | UDP-D-galactose | mouse metabolite | 1975 | 1977 | 48.0 | low | 0 | 3 | 0 | 0 | 0 | 0 |
| 2,2-bis(bromomethyl)-1,3-propanediol | | primary alcohol | | 2000 | 2000 | 24.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| fluorescein-5-isothiocyanate | | fluorescein isothiocyanate | | 1993 | 1993 | 31.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| mannose | | D-aldohexose;
D-mannose;
mannopyranose | metabolite | 1975 | 2012 | 36.7 | low | 0 | 31 | 11 | 4 | 1 | 0 |
| ecdysone | | 14alpha-hydroxy steroid;
22-hydroxy steroid;
25-hydroxy steroid;
2beta-hydroxy steroid;
3beta-sterol;
6-oxo steroid;
ecdysteroid | prohormone | 1982 | 1987 | 39.5 | low | 0 | 2 | 0 | 0 | 0 | 0 |
| limonene | | cycloalkene;
p-menthadiene | human metabolite | 1995 | 1995 | 29.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| n-nitrodiethylamine | | | | 1987 | 1987 | 37.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
| manganese | | elemental manganese;
manganese group element atom | Escherichia coli metabolite;
micronutrient | 1975 | 1977 | 47.9 | low | 0 | 7 | 0 | 0 | 0 | 0 |
| acetylglucosamine | | N-acetyl-D-glucosamine | epitope | 1975 | 1999 | 42.3 | low | 0 | 19 | 5 | 0 | 0 | 0 |
| galactosamine | | D-galactosamine;
primary amino compound | toxin | 1987 | 1987 | 37.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
| isopentenyladenosine | | N-ribosyl-N(6)-isopentenyladenine;
nucleoside analogue | antineoplastic agent;
plant growth regulator;
plant metabolite | 1981 | 1985 | 41.0 | low | 0 | 2 | 0 | 0 | 0 | 0 |
| ozone | | elemental molecule;
gas molecular entity;
reactive oxygen species;
triatomic oxygen | antiseptic drug;
disinfectant;
electrophilic reagent;
greenhouse gas;
mutagen;
oxidising agent;
tracer | 1963 | 1987 | 49.0 | low | 0 | 2 | 0 | 0 | 0 | 0 |
| showdomycin | | | | 1998 | 1999 | 25.5 | low | 0 | 0 | 2 | 0 | 0 | 0 |
| fluorides | | halide anion;
monoatomic fluorine | | 1976 | 2000 | 37.8 | low | 0 | 3 | 1 | 0 | 0 | 0 |
| 1-deoxynojirimycin | | 2-(hydroxymethyl)piperidine-3,4,5-triol;
piperidine alkaloid | anti-HIV agent;
anti-obesity agent;
bacterial metabolite;
EC 3.2.1.20 (alpha-glucosidase) inhibitor;
hepatoprotective agent;
hypoglycemic agent;
plant metabolite | 1989 | 1989 | 35.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
| iodine | | halide anion;
monoatomic iodine | human metabolite | 2006 | 2006 | 18.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| phenyl acetate | | benzenes;
phenyl acetates | | 1978 | 2003 | 38.0 | low | 0 | 16 | 4 | 1 | 0 | 0 |
| 8-bromo cyclic adenosine monophosphate | | 3',5'-cyclic purine nucleotide;
adenyl ribonucleotide;
organobromine compound | antidepressant;
protein kinase agonist | 1996 | 1996 | 28.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| transferrin | | | | 1998 | 2014 | 19.0 | low | 0 | 0 | 2 | 2 | 2 | 0 |
| acetylgalactosamine | | N-acetyl-D-hexosamine;
N-acetylgalactosamine | Escherichia coli metabolite;
human metabolite;
mouse metabolite | 2000 | 2000 | 24.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| colforsin | | acetate ester;
cyclic ketone;
labdane diterpenoid;
organic heterotricyclic compound;
tertiary alpha-hydroxy ketone;
triol | adenylate cyclase agonist;
anti-HIV agent;
antihypertensive agent;
plant metabolite;
platelet aggregation inhibitor;
protein kinase A agonist | 1996 | 1996 | 28.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| swainsonine | | indolizidine alkaloid | antineoplastic agent;
EC 3.2.1.114 (mannosyl-oligosaccharide 1,3-1,6-alpha-mannosidase) inhibitor;
immunological adjuvant;
plant metabolite | 1995 | 1995 | 29.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| lovastatin | | delta-lactone;
fatty acid ester;
hexahydronaphthalenes;
polyketide;
statin (naturally occurring) | anticholesteremic drug;
antineoplastic agent;
Aspergillus metabolite;
prodrug | 1979 | 2007 | 32.7 | low | 0 | 10 | 12 | 2 | 0 | 0 |
| castanospermine | | indolizidine alkaloid | anti-HIV-1 agent;
anti-inflammatory agent;
EC 3.2.1.* (glycosidase) inhibitor;
metabolite | 1992 | 1992 | 32.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| simvastatin | | delta-lactone;
fatty acid ester;
hexahydronaphthalenes;
statin (semi-synthetic) | EC 1.1.1.34/EC 1.1.1.88 (hydroxymethylglutaryl-CoA reductase) inhibitor;
EC 3.4.24.83 (anthrax lethal factor endopeptidase) inhibitor;
ferroptosis inducer;
geroprotector;
prodrug | 1990 | 2016 | 21.0 | low | 0 | 0 | 1 | 0 | 1 | 0 |
| pravastatin | | 3-hydroxy carboxylic acid;
carbobicyclic compound;
carboxylic ester;
hydroxy monocarboxylic acid;
secondary alcohol;
statin (semi-synthetic) | anticholesteremic drug;
environmental contaminant;
metabolite;
xenobiotic | 1991 | 1993 | 32.0 | low | 0 | 0 | 2 | 0 | 0 | 0 |
| atorvastatin | | aromatic amide;
dihydroxy monocarboxylic acid;
monofluorobenzenes;
pyrroles;
statin (synthetic) | environmental contaminant;
xenobiotic | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| glucose, (beta-d)-isomer | | D-glucopyranose | epitope;
mouse metabolite | 1977 | 1981 | 45.0 | low | 0 | 2 | 0 | 0 | 0 | 0 |
| mevastatin | | 2-pyranones;
carboxylic ester;
hexahydronaphthalenes;
polyketide;
statin (naturally occurring) | antifungal agent;
apoptosis inducer;
EC 3.4.24.83 (anthrax lethal factor endopeptidase) inhibitor;
fungal metabolite;
Penicillium metabolite | 1979 | 2001 | 35.0 | low | 0 | 5 | 2 | 1 | 0 | 0 |
| fluorexon | | xanthene dye | fluorochrome | 1987 | 1987 | 37.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
| 25-hydroxycholesterol | | 25-hydroxy steroid;
oxysterol | human metabolite | 1986 | 1989 | 37.0 | low | 0 | 4 | 0 | 0 | 0 | 0 |
| pyrrolidine dithiocarbamate | | dithiocarbamic acids;
pyrrolidines | anticonvulsant;
antineoplastic agent;
geroprotector;
neuroprotective agent;
NF-kappaB inhibitor;
radical scavenger | 2007 | 2007 | 17.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| lathosterol | | 3beta-sterol;
C27-steroid;
cholestanoid;
Delta(7)-sterol | human metabolite;
mouse metabolite | 1991 | 1991 | 33.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| artemisinin | | organic peroxide;
sesquiterpene lactone | antimalarial;
plant metabolite | 1986 | 1986 | 38.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
| tyloxapol | | | | 1998 | 1998 | 26.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| leupeptin | | aldehyde;
tripeptide | bacterial metabolite;
calpain inhibitor;
cathepsin B inhibitor;
EC 3.4.21.4 (trypsin) inhibitor;
serine protease inhibitor | 1989 | 1992 | 34.0 | low | 0 | 2 | 1 | 0 | 0 | 0 |
| octadecyl palmitate | | hexadecanoate ester;
wax ester | coral metabolite;
cosmetic | 1981 | 1981 | 43.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
| nicotine | | 3-(1-methylpyrrolidin-2-yl)pyridine | anxiolytic drug;
biomarker;
immunomodulator;
mitogen;
neurotoxin;
nicotinic acetylcholine receptor agonist;
peripheral nervous system drug;
phytogenic insecticide;
plant metabolite;
psychotropic drug;
teratogenic agent;
xenobiotic | 2003 | 2003 | 21.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| 7-ketocholesterol | | 3beta-hydroxy-Delta(5)-steroid;
3beta-sterol;
7-oxo steroid;
cholestanoid | neuroprotective agent | 1992 | 1992 | 32.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| n(6)-(delta(2)-isopentenyl)adenine | | 6-isopentenylaminopurine | cytokinin | 1981 | 1985 | 41.0 | low | 0 | 2 | 0 | 0 | 0 | 0 |
| 4-nitrophenyl alpha-glucoside | | alpha-D-glucoside;
C-nitro compound;
monosaccharide derivative | chromogenic compound | 1981 | 1981 | 43.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
| glycidyl nitrate | | | | 1981 | 1999 | 34.0 | low | 0 | 1 | 1 | 0 | 0 | 0 |
| cobalt | | cobalt group element atom;
metal allergen | micronutrient | 1976 | 1987 | 42.5 | low | 0 | 2 | 0 | 0 | 0 | 0 |
| deoxyglucose | | | | 1976 | 2020 | 32.0 | low | 0 | 2 | 0 | 0 | 1 | 0 |
| pentosidine | | imidazopyridine;
non-proteinogenic L-alpha-amino acid | biomarker;
cross-linking reagent | 2004 | 2004 | 20.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| n-(n-(3-carboxyoxirane-2-carbonyl)leucyl)isoamylamine | | leucine derivative | | 1989 | 1992 | 33.5 | low | 0 | 1 | 1 | 0 | 0 | 0 |
| n-acetylglucosaminylasparagine | | amino acid zwitterion;
glucosaminylamine;
N(4)-glycosyl-L-asparagine | | 1990 | 1990 | 34.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| 3-azido-2,7-naphthalene disulfonate | | | | 2006 | 2006 | 18.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| xylose | | D-xylose | | 1976 | 1976 | 48.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
| phytol | | | | 1982 | 1982 | 42.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
| tempocholine | | | | 1984 | 1984 | 40.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
| erythritol | | butane-1,2,3,4-tetrol | antioxidant;
human metabolite;
plant metabolite | 2004 | 2017 | 14.3 | low | 0 | 0 | 0 | 2 | 1 | 0 |
| deoxycholic acid | | bile acid;
C24-steroid;
dihydroxy-5beta-cholanic acid | human blood serum metabolite | 1978 | 1982 | 44.0 | low | 0 | 2 | 0 | 0 | 0 | 0 |
| 3-nitrotyrosine | | 2-nitrophenols;
C-nitro compound;
nitrotyrosine;
non-proteinogenic alpha-amino acid | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| lanosterol | | 14alpha-methyl steroid;
3beta-sterol;
tetracyclic triterpenoid | bacterial metabolite;
human metabolite;
mouse metabolite;
plant metabolite;
Saccharomyces cerevisiae metabolite | 1983 | 1983 | 41.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
| leupeptins | | | | 1989 | 1992 | 34.0 | low | 0 | 2 | 1 | 0 | 0 | 0 |
| n-acetylneuraminic acid | | N-acetylneuraminic acids | antioxidant;
bacterial metabolite;
EC 3.2.1.18 (exo-alpha-sialidase) inhibitor;
human metabolite;
mouse metabolite | 1995 | 1995 | 29.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| glucosamine | | D-glucosamine | Escherichia coli metabolite;
geroprotector;
mouse metabolite | 1975 | 2002 | 40.1 | low | 0 | 13 | 2 | 1 | 0 | 0 |
| mevalonic acid | | 3,5-dihydroxy-3-methylpentanoic acid | | 1978 | 2023 | 30.9 | low | 0 | 35 | 35 | 9 | 3 | 2 |
| 7-dehydrocholesterol | | 3beta-hydroxy-Delta(5)-steroid;
3beta-sterol;
cholestanoid;
Delta(5),Delta(7)-sterol | human metabolite;
mouse metabolite | 1988 | 2013 | 23.5 | low | 0 | 1 | 0 | 0 | 1 | 0 |
| inositol 1,4,5-trisphosphate | | myo-inositol trisphosphate | mouse metabolite | 2001 | 2001 | 23.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| ouabain | | 11alpha-hydroxy steroid;
14beta-hydroxy steroid;
5beta-hydroxy steroid;
alpha-L-rhamnoside;
cardenolide glycoside;
steroid hormone | anti-arrhythmia drug;
cardiotonic drug;
EC 2.3.3.1 [citrate (Si)-synthase] inhibitor;
EC 3.1.3.41 (4-nitrophenylphosphatase) inhibitor;
EC 3.6.3.10 (H(+)/K(+)-exchanging ATPase) inhibitor;
EC 3.6.3.9 (Na(+)/K(+)-transporting ATPase) inhibitor;
ion transport inhibitor;
plant metabolite | 1989 | 1989 | 35.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
| puromycin | | puromycins | antiinfective agent;
antimicrobial agent;
antineoplastic agent;
EC 3.4.11.14 (cytosol alanyl aminopeptidase) inhibitor;
EC 3.4.14.2 (dipeptidyl-peptidase II) inhibitor;
nucleoside antibiotic;
protein synthesis inhibitor | 1992 | 1992 | 32.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| desmosterol | | 3beta-hydroxy-Delta(5)-steroid;
3beta-sterol;
C27-steroid;
cholestanoid | human metabolite;
mouse metabolite | 1979 | 1979 | 45.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
| strychnine | | monoterpenoid indole alkaloid;
organic heteroheptacyclic compound | avicide;
cholinergic antagonist;
glycine receptor antagonist;
neurotransmitter agent;
rodenticide | 2003 | 2003 | 21.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| monensin | | cyclic hemiketal;
monocarboxylic acid;
polyether antibiotic;
spiroketal | antifungal agent;
coccidiostat;
ionophore | 1999 | 2001 | 24.0 | low | 0 | 0 | 1 | 1 | 0 | 0 |
| 2-c-methylerythritol 4-phosphate | | tetritol phosphate | Escherichia coli metabolite | 2004 | 2017 | 14.3 | low | 0 | 0 | 0 | 2 | 1 | 0 |
| betadex | | cyclodextrin | | 1993 | 1993 | 31.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| acetyl coenzyme a | | acyl-CoA | acyl donor;
coenzyme;
effector;
fundamental metabolite | 1981 | 2021 | 23.0 | low | 0 | 1 | 0 | 0 | 0 | 1 |
| ergosterol | | 3beta-hydroxy-Delta(5)-steroid;
3beta-sterol;
ergostanoid;
phytosterols | fungal metabolite;
Saccharomyces cerevisiae metabolite | 2000 | 2016 | 16.6 | low | 0 | 0 | 1 | 3 | 1 | 0 |
| tretinoin | | retinoic acid;
vitamin A | anti-inflammatory agent;
antineoplastic agent;
antioxidant;
AP-1 antagonist;
human metabolite;
keratolytic drug;
retinoic acid receptor agonist;
retinoid X receptor agonist;
signalling molecule | 1982 | 2017 | 18.6 | low | 0 | 1 | 1 | 0 | 3 | 0 |
| farnesol | | farnesol | plant metabolite | 1985 | 2013 | 28.5 | low | 0 | 1 | 5 | 1 | 1 | 0 |
| 3-hydroxy-3-methylglutaryl-coenzyme a | | 3-hydroxy-3-methylglutaryl-CoA;
3-hydroxy fatty acyl-CoA | human metabolite;
mouse metabolite | 1987 | 1987 | 37.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
| retinol | | retinol;
vitamin A | human metabolite;
mouse metabolite;
plant metabolite | 1976 | 2005 | 29.6 | low | 0 | 6 | 5 | 7 | 0 | 0 |
| oleic acid | | octadec-9-enoic acid | antioxidant;
Daphnia galeata metabolite;
EC 3.1.1.1 (carboxylesterase) inhibitor;
Escherichia coli metabolite;
mouse metabolite;
plant metabolite;
solvent | 1998 | 2001 | 24.5 | low | 0 | 0 | 1 | 1 | 0 | 0 |
| farnesyl pyrophosphate | | farnesyl diphosphate | Escherichia coli metabolite;
mouse metabolite | 1983 | 2007 | 27.7 | low | 0 | 1 | 2 | 3 | 0 | 0 |
| geranyl pyrophosphate | | polyprenyl diphosphate | Escherichia coli metabolite;
mouse metabolite | 1994 | 2007 | 23.5 | low | 0 | 0 | 1 | 1 | 0 | 0 |
| fosfomycin | | epoxide;
phosphonic acids | antimicrobial agent;
EC 2.5.1.7 (UDP-N-acetylglucosamine 1-carboxyvinyltransferase) inhibitor | 2004 | 2004 | 20.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| geranylgeranyl pyrophosphate | | geranylgeranyl diphosphate | mouse metabolite | 1993 | 2007 | 24.0 | low | 0 | 0 | 1 | 1 | 0 | 0 |
| gw 3965 | | diarylmethane | | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| diethylstilbestrol | | olefinic compound;
polyphenol | antifungal agent;
antineoplastic agent;
autophagy inducer;
calcium channel blocker;
carcinogenic agent;
EC 1.1.1.146 (11beta-hydroxysteroid dehydrogenase) inhibitor;
EC 3.6.3.10 (H(+)/K(+)-exchanging ATPase) inhibitor;
endocrine disruptor;
xenoestrogen | 1977 | 1985 | 43.5 | low | 0 | 4 | 0 | 0 | 0 | 0 |
| dactinomycin | | actinomycin | mutagen | 1989 | 1989 | 35.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
| bromochloroacetic acid | | 2-bromocarboxylic acid;
monocarboxylic acid;
organochlorine compound | | 1976 | 1976 | 48.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
| geraniol | | 3,7-dimethylocta-2,6-dien-1-ol;
monoterpenoid;
primary alcohol | allergen;
fragrance;
plant metabolite;
volatile oil component | 1982 | 1992 | 36.2 | low | 0 | 2 | 2 | 0 | 0 | 0 |
| glycosides | | | | 1977 | 1993 | 41.8 | low | 0 | 5 | 1 | 0 | 0 | 0 |
| isomethyleugenol | | isomethyleugenol | | 1992 | 1992 | 32.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| citral | | enal;
monoterpenoid;
polyprenal | plant metabolite;
volatile oil component | 1982 | 1982 | 42.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
| squalene | | triterpene | human metabolite;
mouse metabolite;
plant metabolite;
Saccharomyces cerevisiae metabolite | 1982 | 1998 | 33.5 | low | 0 | 2 | 4 | 0 | 0 | 0 |
| pyrophosphate | | diphosphate ion | | 1975 | 2007 | 41.5 | low | 0 | 5 | 0 | 1 | 0 | 0 |
| palmitoyl coenzyme a | | 11,12-saturated fatty acyl-CoA;
3-substituted propionyl-CoA;
long-chain fatty acyl-CoA;
palmitoyl bioconjugate | Escherichia coli metabolite;
mouse metabolite | 1988 | 1996 | 32.3 | low | 0 | 1 | 2 | 0 | 0 | 0 |
| sesquiterpenes | | | | 1983 | 2007 | 27.9 | low | 0 | 2 | 2 | 4 | 0 | 0 |
| enclomiphene | | | | 1986 | 1986 | 38.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
| thioguanine anhydrous | | 2-aminopurines | anticoronaviral agent;
antimetabolite;
antineoplastic agent | 1987 | 1987 | 37.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
| thioacetamide | | thiocarboxamide | hepatotoxic agent | 2002 | 2005 | 20.6 | low | 0 | 0 | 0 | 5 | 0 | 0 |
| digoxin | | cardenolide glycoside;
steroid saponin | anti-arrhythmia drug;
cardiotonic drug;
EC 3.6.3.9 (Na(+)/K(+)-transporting ATPase) inhibitor;
epitope | 2001 | 2004 | 21.3 | low | 11 | 0 | 0 | 32 | 0 | 0 |
| tamoxifen | | stilbenoid;
tertiary amino compound | angiogenesis inhibitor;
antineoplastic agent;
bone density conservation agent;
EC 1.2.3.1 (aldehyde oxidase) inhibitor;
EC 2.7.11.13 (protein kinase C) inhibitor;
estrogen antagonist;
estrogen receptor antagonist;
estrogen receptor modulator | 1986 | 1986 | 38.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
| nadp | | | | 1993 | 1996 | 29.5 | low | 0 | 0 | 2 | 0 | 0 | 0 |
| ggti 286 | | | | 2007 | 2007 | 17.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| lithium | | alkali metal atom | | 2006 | 2006 | 18.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| farnesylamine | | | | 1993 | 1993 | 31.0 | medium | 0 | 0 | 1 | 0 | 0 | 0 |
| ovalbumin | | | | 1982 | 1982 | 42.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
| alpha-chymotrypsin | | | | 1977 | 1977 | 47.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
| ubiquinone q2 | | ubiquinones | | 1993 | 1994 | 30.5 | low | 0 | 0 | 2 | 0 | 0 | 0 |
| ubiquinone 9 | | ubiquinones | antioxidant;
human metabolite | 1994 | 1994 | 30.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| undecaprenol | | long-chain primary fatty alcohol;
undecaprenols | | 1977 | 1989 | 40.5 | medium | 0 | 4 | 0 | 0 | 0 | 0 |
| vitamin k semiquinone radical | | | | 1981 | 1981 | 43.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
| 11-cis-retinal | | retinal | chromophore;
human metabolite;
mouse metabolite | 1999 | 2011 | 19.0 | low | 0 | 0 | 1 | 0 | 1 | 0 |
| solanesyl pyrophosphate | | all-trans-polyprenyl diphosphate;
nonaprenyl diphosphate | | 2016 | 2017 | 7.5 | high | 0 | 0 | 0 | 0 | 2 | 0 |
| geranylgeraniol | | geranylgeraniol | | 1981 | 1981 | 43.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
| coenzyme q10 | | ubiquinones | antioxidant;
ferroptosis inhibitor;
human metabolite | 1993 | 2014 | 20.5 | low | 0 | 0 | 1 | 0 | 1 | 0 |
| menaquinone 6 | | | | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| undecaprenyl phosphate | | undecaprenyl phosphate | | 1999 | 1999 | 25.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| methyl linoleate | | fatty acid methyl ester | plant metabolite | 2003 | 2003 | 21.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| brefeldin a | | macrolide antibiotic | Penicillium metabolite | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| xylulose | | xylulose | Escherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite | 2017 | 2017 | 7.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| acipimox | | pyrazinecarboxylic acid | | 2004 | 2004 | 20.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| herbimycin | | 1,4-benzoquinones;
lactam;
macrocycle | antimicrobial agent;
apoptosis inducer;
herbicide;
Hsp90 inhibitor;
tyrosine kinase inhibitor | 2007 | 2007 | 17.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| 1,2-oleoylphosphatidylcholine | | phosphatidylcholine(1+) | | 1986 | 1992 | 35.0 | low | 0 | 1 | 1 | 0 | 0 | 0 |
| nerolidol | | nerolidol | | 2005 | 2005 | 19.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| diphenylhexatriene | | alkatriene | fluorochrome | 1984 | 1987 | 38.5 | low | 0 | 2 | 0 | 0 | 0 | 0 |
| cysteine | | cysteinium | fundamental metabolite | 1997 | 2006 | 22.5 | low | 0 | 0 | 1 | 1 | 0 | 0 |
| s-trans,trans-farnesylthiosalicylic acid | | sesquiterpenoid | | 2004 | 2004 | 20.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| solanesol | | nonaprenol;
primary alcohol | plant metabolite | 1965 | 1985 | 49.0 | low | 0 | 2 | 0 | 0 | 0 | 0 |
| 1,2-dielaidoylphosphatidylethanolamine | | | | 1986 | 1992 | 35.0 | low | 0 | 1 | 1 | 0 | 0 | 0 |
| mevalonolactone | | 4-hydroxy-4-methyloxan-2-one | fungal metabolite;
plant metabolite | 1983 | 2017 | 32.6 | low | 0 | 4 | 0 | 0 | 1 | 0 |
| dolichol monophosphate mannose | | | | 1977 | 2000 | 40.6 | low | 0 | 13 | 2 | 0 | 0 | 0 |
| dehydroergosterol | | 3beta-hydroxy-Delta(5)-steroid;
3beta-sterol;
ergostanoid;
phytosterols | biomarker;
metabolite | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| (2e,4e,6e,10e)-3,7,11,15-tetramethyl-2,4,6,10,14-hexadecapentaenoic acid | | | | 2000 | 2017 | 13.0 | low | 0 | 0 | 1 | 0 | 2 | 0 |
| squalestatin 1 | | acetate ester;
cyclic ketal;
oxabicycloalkane;
polyketide;
tertiary alcohol;
tricarboxylic acid | EC 2.5.1.21 (squalene synthase) inhibitor;
fungal metabolite | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| mannosylretinylphosphate | | retinoid | | 1976 | 1982 | 45.0 | low | 0 | 2 | 0 | 0 | 0 | 0 |
| n-acetyl-s-farnesylcysteine | | sesquiterpenoid | | 1995 | 1995 | 29.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| retinol phosphate | | | | 1976 | 1982 | 45.0 | low | 0 | 2 | 0 | 0 | 0 | 0 |
| nb 598 | | | | 1992 | 1992 | 32.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| cyclosporin g | | | | 1991 | 1991 | 33.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| beta-escin | | | | 2002 | 2003 | 21.2 | low | 1 | 0 | 0 | 4 | 0 | 0 |
| 1-deoxy-2-pentulose | | deoxypentose | Escherichia coli metabolite | 2017 | 2017 | 7.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| ubiquinol | | polyprenylhydroquinone;
ubiquinol | biomarker;
metabolite | 1994 | 2007 | 23.5 | low | 0 | 0 | 1 | 1 | 0 | 0 |
| losartan potassium | | | | 1985 | 2007 | 28.0 | low | 0 | 1 | 0 | 1 | 0 | 0 |
| phytosterols | | | | 2017 | 2017 | 7.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| acid phosphatase | | | | 1979 | 2005 | 35.3 | low | 0 | 2 | 0 | 1 | 0 | 0 |
| mefloquine | | | | 1986 | 1986 | 38.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
| ants | | | | 2006 | 2006 | 18.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| nad | | organophosphate oxoanion | cofactor;
human metabolite;
hydrogen acceptor;
Saccharomyces cerevisiae metabolite | 1987 | 1987 | 37.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
| cytochrome c-t | | | | 2007 | 2007 | 17.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| glucagon | | peptide hormone | | 1997 | 1997 | 27.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| cellulose | | glycoside | | 1978 | 1983 | 43.5 | low | 0 | 2 | 0 | 0 | 0 | 0 |
| phosphatidylcholines | | 1,2-diacyl-sn-glycero-3-phosphocholine | | 1982 | 2001 | 32.8 | low | 0 | 5 | 5 | 1 | 0 | 0 |
| ubiquinone | | | | 1975 | 2018 | 27.4 | low | 11 | 24 | 40 | 39 | 7 | 0 |
| chitosan | | | | 2017 | 2017 | 7.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| bucladesine | | 3',5'-cyclic purine nucleotide | | 1983 | 1983 | 41.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
| dolichol monophosphate | | | | 1982 | 2016 | 32.2 | high | 0 | 29 | 19 | 4 | 4 | 0 |
| dolichol pyrophosphate | | | | 1982 | 2017 | 20.3 | high | 0 | 1 | 1 | 2 | 3 | 0 |
| mannans | | | | 1976 | 2009 | 24.2 | low | 0 | 1 | 2 | 3 | 0 | 0 |
| glycolipids | | | | 1975 | 2005 | 40.5 | low | 0 | 14 | 2 | 3 | 0 | 0 |
| ascorbic acid | | ascorbic acid;
vitamin C | coenzyme;
cofactor;
flour treatment agent;
food antioxidant;
food colour retention agent;
geroprotector;
plant metabolite;
skin lightening agent | 2000 | 2000 | 24.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| salicylates | | monohydroxybenzoate | plant metabolite | 2004 | 2004 | 20.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| epidermal growth factor | | | | 1985 | 1988 | 37.5 | low | 0 | 2 | 0 | 0 | 0 | 0 |
| caseins | | | | 1993 | 1999 | 28.0 | low | 0 | 0 | 3 | 0 | 0 | 0 |
| cyclosporine | | | | 1991 | 1991 | 33.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| guanosine diphosphate mannose | | GDP-D-mannose | Escherichia coli metabolite;
human metabolite;
mouse metabolite;
plant metabolite | 1975 | 2013 | 42.5 | low | 0 | 23 | 2 | 1 | 1 | 0 |
| guanosine triphosphate | | guanosine 5'-phosphate;
purine ribonucleoside 5'-triphosphate | Escherichia coli metabolite;
mouse metabolite;
uncoupling protein inhibitor | 1977 | 1993 | 41.0 | low | 0 | 5 | 1 | 0 | 0 | 0 |
| guanosine | | guanosines;
purines D-ribonucleoside | fundamental metabolite | 1987 | 1987 | 37.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
| inosine | | inosines;
purines D-ribonucleoside | Escherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite | 1987 | 1987 | 37.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
| folic acid | | folic acids;
N-acyl-amino acid | human metabolite;
mouse metabolite;
nutrient | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| cholestyramine resin | | | | 1980 | 1994 | 35.5 | low | 0 | 3 | 3 | 0 | 0 | 0 |
| eye | | | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| concanavalin a | | | | 1982 | 2004 | 32.0 | low | 0 | 3 | 0 | 2 | 0 | 0 |
| phosphorus radioisotopes | | | | 1981 | 1989 | 39.0 | low | 0 | 3 | 0 | 0 | 0 | 0 |
| leptin | | | | 2014 | 2014 | 10.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Condition | Indicated | Studies | First Year | Last Year | Average Age | Relationship Strength | Trials | pre-1990 | 1990's | 2000's | 2010's | post-2020 |
|---|
| 47,XX,+21 | 0 | | 1985 | 1989 | 37.0 | low | 0 | 2 | 0 | 0 | 0 | 0 |
| 7-Dehydrocholesterol Reductase Deficiency | 0 | | 2006 | 2013 | 14.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| Abetalipoproteinemia | 0 | | 1999 | 1999 | 25.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| Abnormalities, Multiple | 0 | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Acquired Immune Deficiency Syndrome | 0 | | 2001 | 2001 | 23.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Acquired Immunodeficiency Syndrome | 0 | | 2001 | 2001 | 23.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Action Myoclonus-Renal Failure Syndrome | 0 | | 2021 | 2021 | 3.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| Acute Confusional Senile Dementia | 0 | | 1982 | 2003 | 34.0 | low | 0 | 5 | 4 | 1 | 0 | 0 |
| Acute Disease | 0 | | 2003 | 2003 | 21.0 | low | 1 | 0 | 0 | 1 | 0 | 0 |
| Acute Liver Injury, Drug-Induced | 0 | | 1984 | 1984 | 40.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
| Acute Rheumatic Fever | 0 | | 2003 | 2003 | 21.0 | low | 1 | 0 | 0 | 1 | 0 | 0 |
| Addison Disease and Cerebral Sclerosis | 0 | | 1999 | 1999 | 25.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| Adrenoleukodystrophy | 0 | | 1999 | 1999 | 25.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| Adult Neuronal Ceroid Lipofuscinosis | 0 | | 1982 | 1992 | 36.7 | low | 0 | 19 | 6 | 0 | 0 | 0 |
| African Sleeping Sickness | 0 | | 2004 | 2004 | 20.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| AGA Deficiency | 0 | | 1992 | 1992 | 32.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| Age-Related Osteoporosis | 0 | | 2003 | 2004 | 20.5 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| Aging | 0 | | 1977 | 2019 | 29.8 | low | 0 | 18 | 19 | 13 | 2 | 0 |
| Albinism | 0 | | 1987 | 1987 | 37.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
| Albinism, Oculocutaneous | 0 | | 1993 | 1993 | 31.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| Albinism, Tyrosinase-Negative | 0 | | 1993 | 1993 | 31.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| Alcohol Abuse | 0 | | 1986 | 2012 | 30.7 | low | 2 | 4 | 7 | 1 | 1 | 0 |
| Alcohol Drinking | 0 | | 1989 | 2012 | 27.2 | low | 1 | 1 | 2 | 0 | 1 | 0 |
| Alcohol Related Neurodevelopmental Disorder | 0 | | 1992 | 2012 | 22.0 | low | 0 | 0 | 1 | 0 | 1 | 0 |
| Alcoholic Cirrhosis | 0 | | 1990 | 2003 | 27.5 | low | 1 | 0 | 1 | 1 | 0 | 0 |
| Alcoholic Fatty Liver | 0 | | 1990 | 1996 | 31.0 | low | 0 | 0 | 3 | 0 | 0 | 0 |
| Alcoholic Intoxication | 0 | | 1989 | 1992 | 33.5 | low | 0 | 1 | 1 | 0 | 0 | 0 |
| Alcoholism | 0 | | 1986 | 2012 | 30.7 | low | 2 | 4 | 7 | 1 | 1 | 0 |
| Alexia | 0 | | 2003 | 2003 | 21.0 | low | 1 | 0 | 0 | 1 | 0 | 0 |
| Alloxan Diabetes | 0 | | 1987 | 1987 | 37.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
| Alogia | 0 | | 2003 | 2003 | 21.0 | low | 1 | 0 | 0 | 1 | 0 | 0 |
| alpha Mannosidase B Deficiency | 0 | | 1990 | 1990 | 34.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| alpha-Mannosidosis | 0 | | 1990 | 1990 | 34.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| Alzheimer Disease | 0 | | 1982 | 2003 | 34.0 | low | 0 | 5 | 4 | 1 | 0 | 0 |
| Amaurotic Familial Idiocy | 0 | | 1988 | 1988 | 36.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
| Amentia | 0 | | 1982 | 1983 | 41.5 | low | 0 | 2 | 0 | 0 | 0 | 0 |
| Anankastic Personality | 0 | | 2002 | 2004 | 21.3 | low | 0 | 0 | 0 | 3 | 0 | 0 |
| Anaplastic Astrocytoma | 0 | | 2001 | 2001 | 23.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Anemia With Multinucleated Erythroblasts | 0 | | 2003 | 2003 | 21.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Angiogenesis, Pathologic | 0 | | 2001 | 2001 | 23.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Angiohemophilia | 0 | | 1987 | 1987 | 37.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
| Antibody Deficiency Syndrome | 0 | | 2003 | 2003 | 21.0 | low | 1 | 0 | 0 | 1 | 0 | 0 |
| Aphasia | 0 | | 2003 | 2003 | 21.0 | low | 1 | 0 | 0 | 1 | 0 | 0 |
| Apolipoprotein B-100, Familial Defective | 0 | | 1991 | 1991 | 33.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| Aprosodia | 0 | | 2003 | 2003 | 21.0 | low | 1 | 0 | 0 | 1 | 0 | 0 |
| Arteriosclerosis | 0 | | 1996 | 1996 | 28.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| Arthritis, Degenerative | 0 | | 1976 | 2003 | 34.5 | low | 0 | 1 | 0 | 1 | 0 | 0 |
| Astrocytoma | 0 | | 2001 | 2001 | 23.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| ATLL | 0 | | 1989 | 1992 | 33.5 | low | 0 | 1 | 1 | 0 | 0 | 0 |
| Autism | 0 | | 2003 | 2003 | 21.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Autism-Dementia-Ataxia-Loss of Purposeful Hand Use Syndrome | 0 | | 1992 | 1992 | 32.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| Autistic Disorder | 0 | | 2003 | 2003 | 21.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| B16 Melanoma | 0 | | 2020 | 2020 | 4.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Bacterial Disease | 0 | | 1989 | 1991 | 34.0 | low | 0 | 1 | 1 | 0 | 0 | 0 |
| Bacterial Infections | 0 | | 1989 | 1991 | 34.0 | low | 0 | 1 | 1 | 0 | 0 | 0 |
| Basedow Disease | 0 | | 2000 | 2000 | 24.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| Behavior Disorders | 0 | | 2002 | 2003 | 21.5 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| Benign Infantile Myoclonic Epilepsy | 0 | | 1991 | 1991 | 33.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| Benign Neoplasms | 0 | | 1989 | 2016 | 25.0 | low | 0 | 1 | 2 | 1 | 1 | 0 |
| Benign Neoplasms, Brain | 0 | | 2001 | 2001 | 23.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Besnier-Boeck Disease | 0 | | 2003 | 2003 | 21.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Bessel-Hagen Disease | 0 | | 2003 | 2003 | 21.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Bile Duct Obstruction | 0 | | 1999 | 1999 | 25.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| Bleb | 0 | | 1993 | 1993 | 31.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| Blood Pressure, High | 0 | | 2004 | 2004 | 20.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Body Weight | 0 | | 1984 | 2000 | 32.0 | low | 0 | 2 | 4 | 0 | 0 | 0 |
| Bone Marrow Diseases | 0 | | 1987 | 1987 | 37.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
| Bowel Diseases, Inflammatory | 0 | | 1998 | 1998 | 26.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| Brain Diseases, Metabolic, Familial | 0 | | 2018 | 2018 | 6.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Brain Neoplasms | 0 | | 2001 | 2001 | 23.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Breast Cancer | 0 | | 1993 | 1993 | 31.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| Breast Neoplasms | 0 | | 1993 | 1993 | 31.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| Bronchitis, Chronic | 0 | | 2003 | 2003 | 21.0 | low | 1 | 0 | 0 | 1 | 0 | 0 |
| Cancer of Colon | 0 | | 1997 | 1997 | 27.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| Cancer of Liver | 0 | | 1982 | 2000 | 34.2 | low | 0 | 7 | 7 | 0 | 0 | 0 |
| Cancer of the Thymus | 0 | | 1985 | 1985 | 39.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
| Cancer of the Thyroid | 0 | | 2000 | 2000 | 24.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| Canine Diseases | 0 | | 1984 | 1991 | 36.7 | low | 0 | 2 | 1 | 0 | 0 | 0 |
| Carbohydrate Metabolism, Inborn Error | 0 | | 2003 | 2013 | 16.0 | low | 0 | 0 | 0 | 5 | 1 | 0 |
| Carbohydrate-Deficient Glycoprotein Syndrome | 0 | | 1995 | 2020 | 15.3 | low | 0 | 0 | 5 | 1 | 13 | 0 |
| Carbon Tetrachloride Poisoning | 0 | | 1990 | 1990 | 34.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| Carcinoma, Ehrlich Tumor | 0 | | 1980 | 1980 | 44.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
| Carcinoma, Hepatocellular | 0 | | 1985 | 1991 | 35.2 | low | 0 | 5 | 4 | 0 | 0 | 0 |
| Carcinoma, Papillary | 0 | | 2000 | 2000 | 24.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| Cardiomyopathy, Congestive | 0 | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Cardiomyopathy, Dilated | 0 | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Cardiovascular Diseases | 0 | | 1991 | 1991 | 33.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| Cataract | 0 | | 2009 | 2009 | 15.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Cataract, Membranous | 0 | | 2009 | 2009 | 15.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Cell Transformation, Neoplastic | 0 | | 1977 | 2020 | 32.2 | low | 0 | 3 | 1 | 0 | 1 | 0 |
| Cell Transformation, Viral | 0 | | 1987 | 1995 | 33.7 | low | 0 | 2 | 1 | 0 | 0 | 0 |
| Central Nervous System Lupus | 0 | | 2003 | 2003 | 21.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Cerebellar Diseases | 0 | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Cerebral Pseudosclerosis | 0 | | 2003 | 2003 | 21.0 | low | 1 | 0 | 0 | 1 | 0 | 0 |
| Cerebro-Hepato-Renal Syndrome | 0 | | 1999 | 1999 | 25.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| Chemical and Drug Induced Liver Injury | 0 | | 1984 | 1984 | 40.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
| Chemical Dependence | 0 | | 1996 | 1996 | 28.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| Cholera Infantum | 0 | | 1991 | 1991 | 33.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| Cholestasis | 0 | | 1999 | 1999 | 25.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| Chronic Bronchitis | 0 | | 2003 | 2003 | 21.0 | low | 1 | 0 | 0 | 1 | 0 | 0 |
| Chronic Motor and Vocal Tic Disorder | 0 | | 2002 | 2002 | 22.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Cirrhoses, Experimental Liver | 0 | | 2005 | 2005 | 19.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Cirrhosis, Liver | 0 | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| CJD (Creutzfeldt-Jakob Disease) | 0 | | 2002 | 2003 | 21.5 | low | 1 | 0 | 0 | 2 | 0 | 0 |
| Colitis Gravis | 0 | | 2003 | 2003 | 21.0 | low | 1 | 0 | 0 | 1 | 0 | 0 |
| Colitis, Granulomatous | 0 | | 2003 | 2003 | 21.0 | low | 1 | 0 | 0 | 1 | 0 | 0 |
| Colitis, Ulcerative | 0 | | 2003 | 2003 | 21.0 | low | 1 | 0 | 0 | 1 | 0 | 0 |
| Colonic Neoplasms | 0 | | 1997 | 1997 | 27.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| Communicable Diseases | 0 | | 1998 | 1998 | 26.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| Compensatory Hyperinsulinemia | 0 | | 2014 | 2014 | 10.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Complications, Pregnancy | 0 | | 1992 | 1992 | 32.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| Condition, Preneoplastic | 0 | | 1991 | 1995 | 31.0 | low | 0 | 0 | 2 | 0 | 0 | 0 |
| Congenital Disorders of Glycosylation | 0 | | 1995 | 2020 | 15.3 | low | 0 | 0 | 5 | 1 | 13 | 0 |
| Creutzfeldt-Jakob Syndrome | 0 | | 2002 | 2003 | 21.5 | low | 1 | 0 | 0 | 2 | 0 | 0 |
| Crohn Disease | 0 | | 2003 | 2003 | 21.0 | low | 1 | 0 | 0 | 1 | 0 | 0 |
| Cystic Fibrosis | 0 | | 1976 | 1976 | 48.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
| Cystic Fibrosis of Pancreas | 0 | | 1976 | 1976 | 48.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
| Deficiency Syndrome, Leukocyte-Adhesion | 0 | | 1998 | 1998 | 26.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| Deficiency, Mental | 0 | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Deficiency, Vitamin A | 0 | | 1976 | 2012 | 31.3 | low | 0 | 1 | 1 | 0 | 1 | 0 |
| Deficiency, Vitamin E | 0 | | 1989 | 1989 | 35.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
| Degenerative Diseases, Central Nervous System | 0 | | 2022 | 2022 | 2.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| Dementia | 0 | | 1982 | 1983 | 41.5 | low | 0 | 2 | 0 | 0 | 0 | 0 |
| Dementia Praecox | 0 | | 2001 | 2001 | 23.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Depression, Involutional | 0 | | 2002 | 2004 | 21.0 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| Depressive Disorder, Major | 0 | | 2002 | 2004 | 21.0 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| Diabetes Mellitus | 0 | | 2014 | 2014 | 10.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Diathesis | 0 | | 2003 | 2020 | 15.3 | low | 2 | 0 | 0 | 2 | 1 | 0 |
| Diffuse Mixed Small and Large Cell Lymphoma | 0 | | 2001 | 2001 | 23.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Dilatation, Pathologic | 0 | | 2003 | 2003 | 21.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Disease Models, Animal | 0 | | 1986 | 2013 | 26.2 | low | 0 | 3 | 3 | 1 | 2 | 0 |
| Disease, Pulmonary | 0 | | 2003 | 2003 | 21.0 | low | 0 | 0 | 0 | 3 | 0 | 0 |
| Diseases of Endocrine System | 0 | | 1991 | 1991 | 33.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| Diseases, Metabolic | 0 | | 2011 | 2014 | 11.5 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| Down Syndrome | 0 | | 1985 | 1989 | 37.0 | low | 0 | 2 | 0 | 0 | 0 | 0 |
| Emphysema | 0 | | 2003 | 2003 | 21.0 | low | 1 | 0 | 0 | 1 | 0 | 0 |
| Encephalitis, Inclusion Body, Measles | 0 | | 2002 | 2002 | 22.0 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| Endocrine System Diseases | 0 | | 1991 | 1991 | 33.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| Epilepsies, Myoclonic | 0 | | 1991 | 1991 | 33.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| Experimental Hepatoma | 0 | | 1983 | 1991 | 36.2 | low | 0 | 2 | 2 | 0 | 0 | 0 |
| Experimental Leukemia | 0 | | 1989 | 1989 | 35.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
| Extravascular Hemolysis | 0 | | 2001 | 2001 | 23.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Eye Diseases | 0 | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Eye Disorders | 0 | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Fatty Liver | 0 | | 1993 | 2010 | 22.5 | low | 0 | 0 | 1 | 1 | 0 | 0 |
| Fatty Liver, Nonalcoholic | 0 | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Fluoride Poisoning | 0 | | 1997 | 2000 | 25.5 | low | 0 | 0 | 2 | 0 | 0 | 0 |
| Froehlich's Syndrome | 0 | | 2004 | 2004 | 20.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Gastroduodenal Ulcer | 0 | | 2003 | 2003 | 21.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Genetic Predisposition | 0 | | 2001 | 2001 | 23.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Germinoblastoma | 0 | | 1988 | 1989 | 35.5 | low | 0 | 2 | 0 | 0 | 0 | 0 |
| Glial Cell Tumors | 0 | | 1995 | 1995 | 29.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| Glioma | 0 | | 1995 | 1995 | 29.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| Granulocytic Leukemia, Chronic | 0 | | 1989 | 1989 | 35.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
| Graves Disease | 0 | | 2000 | 2000 | 24.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| Grippe | 0 | | 1976 | 1976 | 48.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
| Group A Strep Infection | 0 | | 2003 | 2003 | 21.0 | low | 1 | 0 | 0 | 1 | 0 | 0 |
| Habit Chorea | 0 | | 2004 | 2004 | 20.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Hemolysis | 0 | | 2001 | 2001 | 23.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Hemorrhage, Subarachnoid | 0 | | 2003 | 2003 | 21.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Hemorrhagic Diathesis | 0 | | 1987 | 1987 | 37.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
| Hemorrhagic Disorders | 0 | | 1987 | 1987 | 37.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
| Hepatoblastoma | 0 | | 1997 | 1997 | 27.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| Hepatocellular Carcinoma | 0 | | 1985 | 1991 | 35.2 | low | 0 | 5 | 4 | 0 | 0 | 0 |
| Hepatolenticular Degeneration | 0 | | 2003 | 2003 | 21.0 | low | 1 | 0 | 0 | 1 | 0 | 0 |
| Hutchinson Gilford Progeria Syndrome | 0 | | 2003 | 2003 | 21.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Hyper IgD Syndrome | 0 | | 2007 | 2007 | 17.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Hyperglycemia | 0 | | 2014 | 2014 | 10.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Hyperglycemia, Postprandial | 0 | | 2014 | 2014 | 10.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Hyperinsulinism | 0 | | 2014 | 2014 | 10.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Hyperlipoproteinemia | 0 | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Hyperlipoproteinemia Type II | 0 | | 1991 | 1991 | 33.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| Hyperlipoproteinemias | 0 | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Hyperplasia | 0 | | 1987 | 1987 | 37.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
| Hypertension | 0 | | 2004 | 2004 | 20.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Idiopathic Parkinson Disease | 0 | | 2003 | 2003 | 21.0 | low | 1 | 0 | 0 | 1 | 0 | 0 |
| Immunologic Deficiency Syndromes | 0 | | 2003 | 2003 | 21.0 | low | 1 | 0 | 0 | 1 | 0 | 0 |
| Inborn Errors of Metabolism | 0 | | 1987 | 1993 | 34.0 | low | 0 | 1 | 2 | 0 | 0 | 0 |
| Infection, Toxoplasma gondii | 0 | | 2007 | 2007 | 17.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Infections, Orthomyxoviridae | 0 | | 1980 | 1980 | 44.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
| Infectious Diseases | 0 | | 1998 | 1998 | 26.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| Inflammation | 0 | | 1981 | 1988 | 39.5 | low | 0 | 2 | 0 | 0 | 0 | 0 |
| Inflammatory Bowel Diseases | 0 | | 1998 | 1998 | 26.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| Influenza, Human | 0 | | 1976 | 1976 | 48.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
| Injury, Myocardial Reperfusion | 0 | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Innate Inflammatory Response | 0 | | 1981 | 1988 | 39.5 | low | 0 | 2 | 0 | 0 | 0 | 0 |
| Insulin Resistance | 0 | | 2014 | 2014 | 10.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Insulin Sensitivity | 0 | | 2014 | 2014 | 10.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Intellectual Disability | 0 | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Kahler Disease | 0 | | 2003 | 2003 | 21.0 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| Leishmania Infection | 0 | | 2005 | 2005 | 19.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Leishmaniasis | 0 | | 2005 | 2005 | 19.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Leucocythaemia | 0 | | 1989 | 1991 | 34.0 | low | 0 | 1 | 1 | 0 | 0 | 0 |
| Leukemia | 0 | | 1989 | 1991 | 34.0 | low | 0 | 1 | 1 | 0 | 0 | 0 |
| Leukemia-Lymphoma, Adult T-Cell | 0 | | 1989 | 1992 | 33.5 | low | 0 | 1 | 1 | 0 | 0 | 0 |
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 0 | | 1989 | 1989 | 35.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
| Leukocyte-Adhesion Deficiency Syndrome | 0 | | 1998 | 1998 | 26.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| Libman-Sacks Disease | 0 | | 2002 | 2002 | 22.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Lipid Metabolism, Inborn Error | 0 | | 1982 | 1982 | 42.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
| Lipidoses | 0 | | 1991 | 1991 | 33.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| Liver Cirrhosis | 0 | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Liver Cirrhosis, Alcoholic | 0 | | 1990 | 2003 | 27.5 | low | 1 | 0 | 1 | 1 | 0 | 0 |
| Liver Diseases | 0 | | 1999 | 1999 | 25.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| Liver Dysfunction | 0 | | 1999 | 1999 | 25.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| Liver Neoplasms | 0 | | 1982 | 2000 | 34.2 | low | 0 | 7 | 7 | 0 | 0 | 0 |
| Liver Steatosis | 0 | | 1993 | 2010 | 22.5 | low | 0 | 0 | 1 | 1 | 0 | 0 |
| Lung Diseases | 0 | | 2003 | 2003 | 21.0 | low | 0 | 0 | 0 | 3 | 0 | 0 |
| Lupus Erythematosus, Systemic | 0 | | 2002 | 2002 | 22.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Lymphoma | 0 | | 1988 | 1989 | 35.5 | low | 0 | 2 | 0 | 0 | 0 | 0 |
| Lymphoma, Non-Hodgkin | 0 | | 2001 | 2001 | 23.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Lysosomal Enzyme Disorders | 0 | | 1992 | 1994 | 31.0 | low | 0 | 0 | 2 | 0 | 0 | 0 |
| Malaria, Falciparum | 0 | | 2004 | 2014 | 16.7 | low | 0 | 0 | 0 | 2 | 1 | 0 |
| Malignant Melanoma | 0 | | 1997 | 1997 | 27.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| Melanoma | 0 | | 1997 | 1997 | 27.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| Mental Disorders | 0 | | 2002 | 2003 | 21.5 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| Mesenteric Vascular Occlusion | 0 | | 2003 | 2003 | 21.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Metabolic Diseases | 0 | | 2011 | 2014 | 11.5 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| Metabolism, Inborn Errors | 0 | | 1987 | 1993 | 34.0 | low | 0 | 1 | 2 | 0 | 0 | 0 |
| Metaplasia | 0 | | 1976 | 1976 | 48.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
| Metastase | 0 | | 2020 | 2020 | 4.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Mevalonate Kinase Deficiency | 0 | | 2007 | 2007 | 17.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Mucopolysaccharidoses | 0 | | 1985 | 1994 | 34.5 | low | 0 | 1 | 1 | 0 | 0 | 0 |
| Mucopolysaccharidosis | 0 | | 1985 | 1994 | 34.5 | low | 0 | 1 | 1 | 0 | 0 | 0 |
| Multiple Myeloma | 0 | | 2003 | 2003 | 21.0 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| Muscle Disorders | 0 | | 1991 | 1991 | 33.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| Muscular Diseases | 0 | | 1991 | 1991 | 33.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| Myoclonic Jerk | 0 | | 2022 | 2022 | 2.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| Necrosis | 0 | | 2004 | 2004 | 20.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Neoplasm Metastasis | 0 | | 2020 | 2020 | 4.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Neoplasms | 0 | | 1989 | 2016 | 25.0 | low | 0 | 1 | 2 | 1 | 1 | 0 |
| Nerve Degeneration | 0 | | 1994 | 1994 | 30.0 | low | 0 | 0 | 2 | 0 | 0 | 0 |
| Nervous System Diseases | 0 | | 1985 | 2003 | 29.8 | low | 0 | 2 | 0 | 2 | 0 | 0 |
| Nervous System Disorders | 0 | | 1985 | 2003 | 29.8 | low | 0 | 2 | 0 | 2 | 0 | 0 |
| Neurodegenerative Diseases | 0 | | 2022 | 2022 | 2.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| Neuronal Ceroid-Lipofuscinoses | 0 | | 1982 | 1992 | 36.7 | low | 0 | 19 | 6 | 0 | 0 | 0 |
| Neurovisceral Storage Disease with Vertical Supranuclear Ophthalmoplegia | 0 | | 2007 | 2008 | 16.5 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| Niemann-Pick Disease | 0 | | 1995 | 1998 | 27.5 | low | 0 | 0 | 2 | 0 | 0 | 0 |
| Niemann-Pick Disease, Type C | 0 | | 2007 | 2008 | 16.5 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| Niemann-Pick Diseases | 0 | | 1995 | 1998 | 27.5 | low | 0 | 0 | 2 | 0 | 0 | 0 |
| Non-alcoholic Fatty Liver Disease | 0 | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Obsessive-Compulsive Disorder | 0 | | 2002 | 2004 | 21.3 | low | 0 | 0 | 0 | 3 | 0 | 0 |
| Orthomyxoviridae Infections | 0 | | 1980 | 1980 | 44.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
| Osteoarthritis | 0 | | 1976 | 2003 | 34.5 | low | 0 | 1 | 0 | 1 | 0 | 0 |
| Osteophytosis, Spinal | 0 | | 2003 | 2003 | 21.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Osteoporosis | 0 | | 2003 | 2004 | 20.5 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| Ovine Diseases | 0 | | 1986 | 1986 | 38.0 | low | 0 | 2 | 0 | 0 | 0 | 0 |
| Parkinson Disease | 0 | | 2003 | 2003 | 21.0 | low | 1 | 0 | 0 | 1 | 0 | 0 |
| Peptic Ulcer | 0 | | 2003 | 2003 | 21.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Pharyngitis | 0 | | 2003 | 2003 | 21.0 | low | 1 | 0 | 0 | 1 | 0 | 0 |
| Pigmentary Retinopathy | 0 | | 2011 | 2022 | 9.0 | low | 0 | 0 | 0 | 0 | 3 | 1 |
| Plasmodium falciparum Malaria | 0 | | 2004 | 2014 | 16.7 | low | 0 | 0 | 0 | 2 | 1 | 0 |
| Poisoning, Fluoride | 0 | | 1997 | 2000 | 25.5 | low | 0 | 0 | 2 | 0 | 0 | 0 |
| Precancerous Conditions | 0 | | 1991 | 1995 | 31.0 | low | 0 | 0 | 2 | 0 | 0 | 0 |
| Pregnancy | 0 | | 1978 | 2012 | 32.2 | low | 0 | 4 | 4 | 0 | 1 | 0 |
| Progeria | 0 | | 2003 | 2003 | 21.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Proteinuria | 0 | | 1992 | 1992 | 32.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| Recrudescence | 0 | | 2002 | 2003 | 21.5 | low | 1 | 0 | 0 | 2 | 0 | 0 |
| Respiration Disorders | 0 | | 2004 | 2004 | 20.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Respiratory Tract Diseases | 0 | | 2002 | 2002 | 22.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Retinitis Pigmentosa | 0 | | 2011 | 2022 | 9.0 | low | 0 | 0 | 0 | 0 | 3 | 1 |
| Rett Syndrome | 0 | | 1992 | 1992 | 32.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| Rheumatic Diseases | 0 | | 1991 | 1991 | 33.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| Rheumatism | 0 | | 1991 | 1991 | 33.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| Sarcoidosis | 0 | | 2003 | 2003 | 21.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Sarcoma 180 | 0 | | 1987 | 1987 | 37.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
| Schizophrenia | 0 | | 2001 | 2001 | 23.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Sensitivity and Specificity | 0 | | 1994 | 2006 | 22.0 | low | 0 | 0 | 1 | 2 | 0 | 0 |
| Sex Disorders | 0 | | 2004 | 2004 | 20.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Sexual Dysfunction, Physiological | 0 | | 2004 | 2004 | 20.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Smith-Lemli-Opitz Syndrome | 0 | | 2006 | 2013 | 14.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| Sore Throat | 0 | | 2003 | 2003 | 21.0 | low | 1 | 0 | 0 | 1 | 0 | 0 |
| Streptococcal Infections | 0 | | 2003 | 2003 | 21.0 | low | 1 | 0 | 0 | 1 | 0 | 0 |
| Subarachnoid Hemorrhage | 0 | | 2003 | 2003 | 21.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Substance-Related Disorders | 0 | | 1996 | 1996 | 28.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| Symptom Cluster | 0 | | 1987 | 2010 | 25.5 | low | 0 | 1 | 0 | 1 | 0 | 0 |
| Syndrome | 0 | | 1987 | 2010 | 25.5 | low | 0 | 1 | 0 | 1 | 0 | 0 |
| Tay-Sachs Disease | 0 | | 1988 | 1988 | 36.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
| Thymus Neoplasms | 0 | | 1985 | 1985 | 39.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
| Thyroid Neoplasms | 0 | | 2000 | 2000 | 24.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| Tics | 0 | | 2004 | 2004 | 20.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Tourette Syndrome | 0 | | 2002 | 2002 | 22.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Toxoplasmosis | 0 | | 2007 | 2007 | 17.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Tracheal Diseases | 0 | | 1976 | 1976 | 48.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
| Trypanosomiasis, African | 0 | | 2004 | 2004 | 20.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Vascular Diseases | 0 | | 1998 | 1998 | 26.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| Viral Diseases | 0 | | 1991 | 1991 | 33.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| Virus Diseases | 0 | | 1991 | 1991 | 33.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| Vitamin A Deficiency | 0 | | 1976 | 2012 | 31.3 | low | 0 | 1 | 1 | 0 | 1 | 0 |
| von Willebrand Diseases | 0 | | 1987 | 1987 | 37.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
| Zellweger Syndrome | 0 | | 1999 | 1999 | 25.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
Identification of functional lipid metabolism biomarkers of brown adipose tissue aging.Molecular metabolism, , Volume: 24, 2019
Dolichol: A Component of the Cellular Antioxidant Machinery.Lipids, , Volume: 51, Issue:4, 2016
Accumulation of dolichol in older tissues satisfies the proposed criteria to be qualified a biomarker of aging.The journals of gerontology. Series A, Biological sciences and medical sciences, , Volume: 60, Issue:1, 2005
Ageing and oxidative stress: a role for dolichol in the antioxidant machinery of cell membranes?Journal of Alzheimer's disease : JAD, , Volume: 6, Issue:2, 2004
Changes in dolichol and pentosidine levels in the age-mismatched heterotopically transplanted rat heart.Biogerontology, , Volume: 5, Issue:6, 2004
Anti-aging effects of anti-lipolytic drugs.Experimental gerontology, , Volume: 39, Issue:7, 2004
Dolichol: an essential part in the antioxidant machinery of cell membranes?Biogerontology, , Volume: 4, Issue:6, 2003
Age-related changes of isoprenoid biosynthesis in rat liver and brain.Biogerontology, , Volume: 4, Issue:6, 2003
The fate of dolichol in rat cells and tissues.Biogerontology, , Volume: 4, Issue:6, 2003
Effect of increasing age on tissue dolichol levels in ad libitum fed and food-restricted rats.Biogerontology, , Volume: 4, Issue:6, 2003
The age-related accumulation of dolichol in rat liver may correlate with expectation of life.Biogerontology, , Volume: 4, Issue:2, 2003
Age-related changes of cholesterol and dolichol biosynthesis in rat liver.Mechanisms of ageing and development, , Apr-30, Volume: 123, Issue:8, 2002
Low level dietary restriction retards age-related dolichol accumulation.Aging clinical and experimental research, , Volume: 14, Issue:2, 2002
Dolichol levels in younger and older rat hearts heterotopically transplanted in younger recipients.Lipids, , Volume: 37, Issue:9, 2002
Effects of ageing and increased haemolysis on the levels of dolichol in rat spleen.Experimental gerontology, , Volume: 37, Issue:1, 2001
Regulation of ubiquinone metabolism.Free radical biology & medicine, , Volume: 29, Issue:3-4, 2000
Elevation of ubiquinone content by peroxisomal inducers in rat liver during aging.Chemico-biological interactions, , Nov-06, Volume: 116, Issue:1-2, 1998
A proposed mechanism of the antiaging action of diet restriction.Aging (Milan, Italy), , Volume: 10, Issue:2, 1998
Age-dependent accumulation of dolichol in rat liver: is tissue dolichol a biomarker of aging?The journals of gerontology. Series A, Biological sciences and medical sciences, , Volume: 53, Issue:2, 1998
Accumulation of dolichol and impaired signal transduction in aging.Aging (Milan, Italy), , Volume: 9, Issue:6, 1997
Effects of aging and diet on the accumulation of dolichol in rat tissues.Biochemistry and cell biology = Biochimie et biologie cellulaire, , Volume: 74, Issue:2, 1996
Age-dependent modifications in the metabolism of mevalonate pathway lipids in rat brain.Mechanisms of ageing and development, , Nov-03, Volume: 85, Issue:1, 1995
Dolichols and proliferating systems.Acta biochimica Polonica, , Volume: 41, Issue:3, 1994
Age-dependent changes in rat liver prenyltransferases.Mechanisms of ageing and development, , Oct-20, Volume: 76, Issue:2-3, 1994
Elevated levels of dolichol in the brains of mucopolysaccharidosis and related disorders.Molecular and chemical neuropathology, , Volume: 22, Issue:2, 1994
Isoprenoids in aging and neurodegeneration.Neurochemistry international, , Volume: 25, Issue:1, 1994
Changes with ageing in total dolichol and dolichol fractions in Drosophila.Mechanisms of ageing and development, , Volume: 67, Issue:1-2, 1993
Dolichol: function, metabolism, and accumulation in human tissues.Biochemistry and cell biology = Biochimie et biologie cellulaire, , Volume: 70, Issue:6, 1992
Protease inhibition causes some manifestations of aging and Alzheimer's disease in rodent and primate brain.Annals of the New York Academy of Sciences, , Dec-31, Volume: 674, 1992
Ubiquinone, dolichol, and cholesterol metabolism in aging and Alzheimer's disease.Biochemistry and cell biology = Biochimie et biologie cellulaire, , Volume: 70, Issue:6, 1992
Dolichol levels during development and ageing of Drosophila melanogaster.Comparative biochemistry and physiology. B, Comparative biochemistry, , Volume: 98, Issue:2-3, 1991
Lipid compositions of different regions of the human brain during aging.Journal of neurochemistry, , Volume: 54, Issue:2, 1990
Phosphorylated dolichols in aging.The Biochemical journal, , Feb-01, Volume: 265, Issue:3, 1990
Changes in murine tissue concentrations of dolichol and dolichol derivatives associated with age.Lipids, , Volume: 25, Issue:10, 1990
Age-associated changes in dolichol and dolichyl phosphate metabolism in the kidneys and liver of mice.Biochimica et biophysica acta, , Aug-08, Volume: 1004, Issue:2, 1989
Age-related changes in the lipid compositions of rat and human tissues.Lipids, , Volume: 24, Issue:7, 1989
Morphological, physiological and biochemical alterations in livers of rodents induced by protease inhibitors: a comparison with old livers.Advances in experimental medicine and biology, , Volume: 266, 1989
Membrane properties of dolichol in different age groups of mice.Chemistry and physics of lipids, , Volume: 51, Issue:3-4, 1989
Age-associated decrease of total dolichol in human serum.Clinica chimica acta; international journal of clinical chemistry, , Oct-16, Volume: 184, Issue:3, 1989
Dolichyl phosphate: rapid increase and predominant form of brain dolichol compounds during early brain development.Developmental neuroscience, , Volume: 10, Issue:1, 1988
Dolichol-linked glycoprotein synthesis in developing mammalian brain: maturational changes of the N-acetylglucosaminylphosphotransferase.Brain research, , Volume: 430, Issue:2, 1987
Age-dependent changes in the levels of dolichol and dolichyl phosphates in human brain.Acta chemica Scandinavica. Series B: Organic chemistry and biochemistry, , Volume: 41, Issue:2, 1987
Distribution of dolichol and dolichyl phosphate in human brain.Journal of neurochemistry, , Volume: 49, Issue:3, 1987
Quantitation of dolichyl phosphate and dolichol in major organs of the rat as a function of age.Lipids, , Volume: 21, Issue:5, 1986
Rat testicular dolichols: distribution and accumulation with age.Biology of reproduction, , Volume: 34, Issue:1, 1986
Age-associated increase of free dolichol levels in mice.Biochimica et biophysica acta, , May-11, Volume: 793, Issue:3, 1984
The biosynthesis of polyisoprenoid chains.Biochemical Society transactions, , Volume: 11, Issue:5, 1983
High levels of brain dolichols in neuronal ceroid-lipofuscinosis and senescence.Journal of neurochemistry, , Volume: 40, Issue:5, 1983
Raised levels of cerebral cortex dolichols in Alzheimer's disease.Lancet (London, England), , Jul-10, Volume: 2, Issue:8289, 1982
Accumulation of dolichols in brains of elderly.The Journal of biological chemistry, , Jun-10, Volume: 257, Issue:11, 1982
Elevated cholesterol and dolichol synthesis in mouse pachytene spermatocytes.The Journal of biological chemistry, , Jul-25, Volume: 256, Issue:14, 1981
Increase in the lipid intermediate pathway of protein glycosylation during hen oviduct differentiation.The Journal of biological chemistry, , Jun-25, Volume: 252, Issue:12, 1977
The lipid compositions of different regions of rat brain during development and aging.Neurobiology of aging, , Volume: 17, Issue:6
Glycosylation defects underlying fetal alcohol spectrum disorder: a novel pathogenetic model. "When the wine goes in, strange things come out" - S.T. Coleridge, The Piccolomini.Journal of inherited metabolic disease, , Volume: 35, Issue:3, 2012
A study of urinary dolichols as a biological marker for alcohol abuse. Report 2: Comparison of urinary dolichols/creatinine concentrations among non-drinkers, moderate-drinkers and heavy-drinkers.Arukoru kenkyu to yakubutsu izon = Japanese journal of alcohol studies & drug dependence, , Volume: 29, Issue:5, 1994
Effect of alcohol on urinary and blood dolichols.Biochemistry and cell biology = Biochimie et biologie cellulaire, , Volume: 70, Issue:6, 1992
Effect of alcohol on blood dolichol concentration.Alcoholism, clinical and experimental research, , Volume: 13, Issue:4, 1989
Effect of heavy weekend drinking on urinary dolichol levels.Alcohol (Fayetteville, N.Y.), , Volume: 4, Issue:6
Effects of moderate drinking and alcohol abstinence on urinary dolichol levels.Alcohol (Fayetteville, N.Y.), , Volume: 5, Issue:3
Glycosylation defects underlying fetal alcohol spectrum disorder: a novel pathogenetic model. "When the wine goes in, strange things come out" - S.T. Coleridge, The Piccolomini.Journal of inherited metabolic disease, , Volume: 35, Issue:3, 2012
Hypothalamic digoxin and isoprenoid pathway dysfunction relation to alcoholic addiction, alcoholic cirrhosis, and acquired hepatocerebral degeneration--relation to hemispheric chemical dominance.The International journal of neuroscience, , Volume: 113, Issue:4, 2003
Effect of chronic ethanol consumption on glycosylation processes in rat liver microsomes and Golgi apparatus.Alcohol and alcoholism (Oxford, Oxfordshire), , Volume: 31, Issue:1, 1996
A study of urinary dolichols as a biological marker for alcohol abuse. Report 2: Comparison of urinary dolichols/creatinine concentrations among non-drinkers, moderate-drinkers and heavy-drinkers.Arukoru kenkyu to yakubutsu izon = Japanese journal of alcohol studies & drug dependence, , Volume: 29, Issue:5, 1994
A study of urinary dolichols as a biological marker for alcohol abuse. Report 1: Quantitation of urinary dolichols by high performance liquid chromatography after BondElutC18 (500 mg) cartridge extraction.Arukoru kenkyu to yakubutsu izon = Japanese journal of alcohol studies & drug dependence, , Volume: 29, Issue:3, 1994
Effect of alcohol on urinary and blood dolichols.Biochemistry and cell biology = Biochimie et biologie cellulaire, , Volume: 70, Issue:6, 1992
Gamma-glutamyltransferase, aspartate and alanine aminotransferases and their ratio, mean cell volume and urinary dolichol in pregnant alcohol abusers.British journal of obstetrics and gynaecology, , Volume: 99, Issue:4, 1992
Urinary dolichol--a doubtful marker of alcoholism.Alcoholism, clinical and experimental research, , Volume: 15, Issue:6, 1991
Brain and liver dolichol in chronic alcoholism: a necropsy study.Alcoholism, clinical and experimental research, , Volume: 14, Issue:4, 1990
Effect of alcohol on blood dolichol concentration.Alcoholism, clinical and experimental research, , Volume: 13, Issue:4, 1989
Urinary dolichol--a new marker of alcoholism.Alcoholism, clinical and experimental research, , Volume: 11, Issue:6, 1987
Blood acetate and urinary dolichols--new markers of heavy drinking and alcoholism.Progress in clinical and biological research, , Volume: 241, 1987
Liquid-chromatographic determination of dolichols in urine.Clinical chemistry, , Volume: 32, Issue:11, 1986
Elevated urinary dolichol levels in chronic alcoholics.Alcoholism, clinical and experimental research, , Volume: 9, Issue:1
[Biomarkers of alcohol abuse. Part II. New biomarkers and their interpretation].Psychiatria polska, , Volume: 44, Issue:1
Hypothalamic digoxin, hemispheric chemical dominance, and Alzheimer's disease.The International journal of neuroscience, , Volume: 113, Issue:3, 2003
Isoprenoids in aging and neurodegeneration.Neurochemistry international, , Volume: 25, Issue:1, 1994
Lipid composition in different regions of the brain in Alzheimer's disease/senile dementia of Alzheimer's type.Journal of neurochemistry, , Volume: 59, Issue:5, 1992
Ubiquinone, dolichol, and cholesterol metabolism in aging and Alzheimer's disease.Biochemistry and cell biology = Biochimie et biologie cellulaire, , Volume: 70, Issue:6, 1992
Protease inhibition causes some manifestations of aging and Alzheimer's disease in rodent and primate brain.Annals of the New York Academy of Sciences, , Dec-31, Volume: 674, 1992
Lipid abnormalities in the brain in adult Down's syndrome and Alzheimer's disease.Molecular and chemical neuropathology, , Volume: 11, Issue:3, 1989
Dolichol and dolichyl phosphate in the neuronal ceroid-lipofuscinoses and other diseases.American journal of medical genetics. Supplement, , Volume: 5, 1988
Dolichols are elevated in brain tissue from Alzheimer's disease, but not in urinary sediment from Alzheimer's disease and Down's syndrome.Neurochemical pathology, ,Winter, Volume: 3, Issue:4, 1985
High levels of brain dolichols in neuronal ceroid-lipofuscinosis and senescence.Journal of neurochemistry, , Volume: 40, Issue:5, 1983
Raised levels of cerebral cortex dolichols in Alzheimer's disease.Lancet (London, England), , Jul-10, Volume: 2, Issue:8289, 1982
The effects of anabolic androgenic steroids on serum ubiquinone and dolichol levels among steroid abusers.Metabolism: clinical and experimental, , Volume: 45, Issue:7, 1996
Variations in serum levels of dolichol and its occurrence in human atherosclerotic plaques.Biochemistry and cell biology = Biochimie et biologie cellulaire, , Volume: 72, Issue:1-2
Microenvironment of endothelial cell growth and regulation of protein N-glycosylation.Indian journal of biochemistry & biophysics, , Volume: 25, Issue:1-2
Isoprenoid pathway-related membrane dysfunction in neuropsychiatric disorders.The International journal of neuroscience, , Volume: 113, Issue:11, 2003
Hypothalamic digoxin, hemispheric dominance, and neuroimmune integration.The International journal of neuroscience, , Volume: 112, Issue:4, 2002
High levels of brain dolichols in neuronal ceroid-lipofuscinosis and senescence.Journal of neurochemistry, , Volume: 40, Issue:5, 1983
Raised levels of cerebral cortex dolichols in Alzheimer's disease.Lancet (London, England), , Jul-10, Volume: 2, Issue:8289, 1982
Lipid abnormalities in the brain in adult Down's syndrome and Alzheimer's disease.Molecular and chemical neuropathology, , Volume: 11, Issue:3, 1989
Dolichols are elevated in brain tissue from Alzheimer's disease, but not in urinary sediment from Alzheimer's disease and Down's syndrome.Neurochemical pathology, ,Winter, Volume: 3, Issue:4, 1985
Hypothalamic digoxin-mediated model for trisomy 21.Pediatric pathology & molecular medicine, , Volume: 22, Issue:5
Modulation of metabolism in HepG2 cells upon treatment with cyclosporin A and Nva2-cyclosporin.Experimental and molecular pathology, , Volume: 54, Issue:3, 1991
Dolichol biosynthesis in human malignant cells.The Biochemical journal, , Sep-15, Volume: 278 ( Pt 3), 1991
Studies on the biosynthesis of polyisoprenols, cholesterol and ubiquinone in highly differentiated human hepatomas.Journal of experimental pathology (Oxford, England), , Volume: 71, Issue:2, 1990
Studies on the polyisoprenoid composition in hepatocellular carcinomas and its correlation with their differentiation.APMIS : acta pathologica, microbiologica, et immunologica Scandinavica, , Volume: 98, Issue:6, 1990
Polyisoprenoid, cholesterol and ubiquinone levels in human hepatocellular carcinomas.British journal of experimental pathology, , Volume: 70, Issue:1, 1989
Cytidine 5'-triphosphate-dependent dolichol kinase and dolichol phosphatase activities and levels of dolichyl phosphate in microsomal fractions from highly differentiated human hepatomas.Cancer research, , Jun-15, Volume: 48, Issue:12, 1988
The lipid composition of highly differentiated human hepatomas, with special reference to fatty acids.British journal of experimental pathology, , Volume: 69, Issue:5, 1988
Biosynthesis of sterols and dolichol in human hepatomas.Acta chemica Scandinavica. Series B: Organic chemistry and biochemistry, , Volume: 41, Issue:1, 1987
Polyprenol content in primary human liver carcinoma.Acta chemica Scandinavica. Series B: Organic chemistry and biochemistry, , Volume: 39, Issue:4, 1985
Hypothalamic-mediated model for Creutzfeldt-Jakob disease: relation to hemispheric chemical dominance.The International journal of neuroscience, , Volume: 113, Issue:7, 2003
Hypothalamic digoxin, hemispheric dominance, and neuroimmune integration.The International journal of neuroscience, , Volume: 112, Issue:4, 2002
Hypothalamic digoxin and isoprenoid pathway dysfunction relation to alcoholic addiction, alcoholic cirrhosis, and acquired hepatocerebral degeneration--relation to hemispheric chemical dominance.The International journal of neuroscience, , Volume: 113, Issue:4, 2003
Brain and liver dolichol in chronic alcoholism: a necropsy study.Alcoholism, clinical and experimental research, , Volume: 14, Issue:4, 1990
Regulation of ubiquinone metabolism.Free radical biology & medicine, , Volume: 29, Issue:3-4, 2000
Evidence for protein dolichylation.FEBS letters, , Oct-27, Volume: 416, Issue:3, 1997
Enzymes of the mevalonate pathway in rat liver nodules induced by 2-acetylaminofluorene treatment.Carcinogenesis, , Volume: 16, Issue:3, 1995
Dolichol biosynthesis in human malignant cells.The Biochemical journal, , Sep-15, Volume: 278 ( Pt 3), 1991
Modulation of metabolism in HepG2 cells upon treatment with cyclosporin A and Nva2-cyclosporin.Experimental and molecular pathology, , Volume: 54, Issue:3, 1991
Studies on the biosynthesis of polyisoprenols, cholesterol and ubiquinone in highly differentiated human hepatomas.Journal of experimental pathology (Oxford, England), , Volume: 71, Issue:2, 1990
Studies on the polyisoprenoid composition in hepatocellular carcinomas and its correlation with their differentiation.APMIS : acta pathologica, microbiologica, et immunologica Scandinavica, , Volume: 98, Issue:6, 1990
Polyisoprenoid, cholesterol and ubiquinone levels in human hepatocellular carcinomas.British journal of experimental pathology, , Volume: 70, Issue:1, 1989
Cytidine 5'-triphosphate-dependent dolichol kinase and dolichol phosphatase activities and levels of dolichyl phosphate in microsomal fractions from highly differentiated human hepatomas.Cancer research, , Jun-15, Volume: 48, Issue:12, 1988
The lipid composition of highly differentiated human hepatomas, with special reference to fatty acids.British journal of experimental pathology, , Volume: 69, Issue:5, 1988
Biosynthesis of sterols and dolichol in human hepatomas.Acta chemica Scandinavica. Series B: Organic chemistry and biochemistry, , Volume: 41, Issue:1, 1987
Polyprenol content in primary human liver carcinoma.Acta chemica Scandinavica. Series B: Organic chemistry and biochemistry, , Volume: 39, Issue:4, 1985
Role of dolichyl phosphate in regulation of protein glycosylation in 2-acetylaminofluorene-induced carcinogenesis in rat liver.Cancer research, , Volume: 44, Issue:2, 1984
Lipid intermediates in glycosylation reactions in preneoplastic nodules of the liver.Acta chemica Scandinavica. Series B: Organic chemistry and biochemistry, , Volume: 36, Issue:8, 1982
Hypothalamic digoxin, hemispheric chemical dominance, and sarcoidosis.The International journal of neuroscience, , Volume: 113, Issue:11, 2003
Hypothalamic digoxin, hemispheric chemical dominance, and interstitial lung disease.The International journal of neuroscience, , Volume: 113, Issue:10, 2003
Hypothalamic digoxin, cerebral chemical dominance, and pathogenesis of pulmonary diseases.The International journal of neuroscience, , Volume: 113, Issue:2, 2003
Significant increases in urinary dolichol levels in bacterial infections, malignancies and pregnancy but not in other clinical conditions.Annals of medicine, , Volume: 21, Issue:1, 1989
The phenotype of five classes of T lymphoma mutants. Defective glycophospholipid anchoring, rapid degradation, and secretion of Thy-1 glycoprotein.The Journal of biological chemistry, , Jan-25, Volume: 263, Issue:3, 1988
Mutation of Nogo-B receptor, a subunit of cis-prenyltransferase, causes a congenital disorder of glycosylation.Cell metabolism, , Sep-02, Volume: 20, Issue:3, 2014
From glycosylation disorders to dolichol biosynthesis defects: a new class of metabolic diseases.Journal of inherited metabolic disease, , Volume: 34, Issue:4, 2011
Decreased plasma ubiquinone-10 concentration in patients with mevalonate kinase deficiency.Pediatric research, , Volume: 34, Issue:2, 1993
Elevated levels of serum dolichol in aspartylglucosaminuria.Life sciences, , Volume: 47, Issue:7, 1990
Elevated urinary dolichol excretion in the Hermansky-Pudlak syndrome. Indicator of lysosomal dysfunction.The American journal of medicine, , Volume: 82, Issue:3, 1987
Isoprenoid pathway related cascade in multiple myeloma.Pathology oncology research : POR, , Volume: 9, Issue:2, 2003
Hypothalamic digoxin, hemispheric chemical dominance, and oncogenesis: evidence from multiple myeloma.The International journal of neuroscience, , Volume: 113, Issue:12, 2003
In vitro and in vivo downregulation of the ATP binding cassette transporter B1 by the HMG-CoA reductase inhibitor simvastatin.Naunyn-Schmiedeberg's archives of pharmacology, , Volume: 389, Issue:1, 2016
Suppression of dolichol synthesis with isoprenoids and statins may potentiate the cancer-retardant efficacy of IGF-I down-regulation.Medical hypotheses, , Volume: 56, Issue:1, 2001
Glycoproteins and their relationship to human disease.Acta anatomica, , Volume: 161, Issue:1-4, 1998
Serum dolichols in different clinical conditions.Scandinavian journal of clinical and laboratory investigation, , Volume: 51, Issue:8, 1991
Significant increases in urinary dolichol levels in bacterial infections, malignancies and pregnancy but not in other clinical conditions.Annals of medicine, , Volume: 21, Issue:1, 1989
Isoprenoid pathway-related membrane dysfunction in neuropsychiatric disorders.The International journal of neuroscience, , Volume: 113, Issue:11, 2003
Schizoid neurochemical pathology-induced membrane Na(+)-K+ ATPase inhibition in relation to neurological disorders.The International journal of neuroscience, , Volume: 113, Issue:12, 2003
Urinary sediment dolichols in the diagnosis of neuronal ceroid-lipofuscinosis.Annals of neurology, , Volume: 19, Issue:3, 1986
Urinary sediment dolichol excretion in patients with Batten disease and other neurodegenerative and storage disorders.Pediatric research, , Volume: 19, Issue:2, 1985
Blood dolichol in lysosomal diseases.Biochemistry and cell biology = Biochimie et biologie cellulaire, , Volume: 70, Issue:6, 1992
Dolichyl-pyrophosphoryloligosaccharide protein oligosaccharide transferase in neuronal ceroid-lipofuscinosis.Biochemistry and cell biology = Biochimie et biologie cellulaire, , Volume: 70, Issue:6, 1992
Rett syndrome and metabolic disorder.Journal of the American Academy of Child and Adolescent Psychiatry, , Volume: 31, Issue:3, 1992
Perspective of biochemical research in the neuronal ceroid-lipofuscinosis.American journal of medical genetics, , Feb-15, Volume: 42, Issue:4, 1992
Adult type of neuronal ceroid lipofuscinosis.Developmental neuroscience, , Volume: 13, Issue:4-5, 1991
Low molecular weight urinary peptides in ceroid-lipofuscinoses: potential biochemical markers for the juvenile subtype.American journal of medical genetics, , Volume: 37, Issue:4, 1990
Analysis of dolichyl pyrophosphoryl oligosaccharides in purified storage cytosomes from ovine ceroid-lipofuscinosis.Biochimica et biophysica acta, , Dec-08, Volume: 993, Issue:2-3, 1989
High-mannose dolichol-linked oligosaccharides in infantile ceroid-lipofuscinosis.Biochemical Society transactions, , Volume: 17, Issue:6, 1989
Clinical and biochemical studies of Japanese neuronal ceroid-lipofuscinosis.American journal of medical genetics. Supplement, , Volume: 5, 1988
Dolichol and dolichyl phosphate in the neuronal ceroid-lipofuscinoses and other diseases.American journal of medical genetics. Supplement, , Volume: 5, 1988
Ceroid-lipofuscinosis. Report of two autopsy cases.Acta pathologica japonica, , Volume: 38, Issue:9, 1988
Normal dolichol concentration in urine sediments from four patients with neuronal ceroid lipofuscinosis (Batten's disease).Journal of inherited metabolic disease, , Volume: 10, Issue:1, 1987
Animal model: ceroidosis (ceroid-lipofuscinosis) in Australian cattle dogs.American journal of medical genetics, , Volume: 26, Issue:4, 1987
Accumulation of phosphorylated dolichol in several tissues in ceroid-lipofuscinosis (Batten disease).Clinica chimica acta; international journal of clinical chemistry, , Volume: 170, Issue:2-3, 1987
Ceroid lipofuscinosis in sheep. II. The major component of the lipopigment in liver, kidney, pancreas, and brain is low molecular weight protein.The Journal of biological chemistry, , Feb-05, Volume: 261, Issue:4, 1986
Ceroid lipofuscinosis in sheep. I. Bis(monoacylglycero)phosphate, dolichol, ubiquinone, phospholipids, fatty acids, and fluorescence in liver lipopigment lipids.The Journal of biological chemistry, , Feb-05, Volume: 261, Issue:4, 1986
Abnormal excretion of autofluorescent lipids in urine from patients with neuronal ceroid lipofuscinosis.The Tohoku journal of experimental medicine, , Volume: 148, Issue:4, 1986
Urinary sediment dolichols in the diagnosis of neuronal ceroid-lipofuscinosis.Annals of neurology, , Volume: 19, Issue:3, 1986
Dolichol and phosphorylated dolichol content of tissues in ceroid-lipofuscinosis.Journal of inherited metabolic disease, , Volume: 8, Issue:4, 1985
Urinary sediment dolichol excretion in patients with Batten disease and other neurodegenerative and storage disorders.Pediatric research, , Volume: 19, Issue:2, 1985
Dolichol metabolism in cultured skin fibroblasts from patients with "neuronal" ceroid lipofuscinosis (Batten's disease).Journal of inherited metabolic disease, , Volume: 7, Issue:3, 1984
Dolichol and dolichyl phosphate levels in brain tissue from English setters with ceroid lipofuscinosis.Journal of neurochemistry, , Volume: 42, Issue:4, 1984
High levels of brain dolichols in neuronal ceroid-lipofuscinosis and senescence.Journal of neurochemistry, , Volume: 40, Issue:5, 1983
Dolichols in brain and urinary sediment in neuronal ceroid lipofuscinosis.Neurology, , Volume: 33, Issue:1, 1983
Batten disease: new research findings on the biochemical defect.Birth defects original article series, , Volume: 18, Issue:6, 1982
Alterations in the biosynthesis of cholesterol, dolichol and dolichyl-P in the genetic cholesterol homeostasis disorder, Niemann-Pick type C disease.Biochimica et biophysica acta, , Nov-02, Volume: 1394, Issue:2-3, 1998
Changes in the levels of dolichol and dolichyl phosphate in a murine model of Niemann-Pick's type C disease.Journal of neurochemistry, , Volume: 65, Issue:2, 1995
Familial hypothalamic digoxin deficiency syndrome.The Journal of neuropsychiatry and clinical neurosciences, ,Winter, Volume: 16, Issue:1, 2004
Familial hypodigoxinemic membrane Na(+)-K(+) ATPase upregulatory syndrome - relation between digoxin status and cerebral dominance.Neurology India, , Volume: 50, Issue:3, 2002
Hypothalamic digoxin deficiency in obsessive compulsive disorder and la Tourette's syndrome.The International journal of neuroscience, , Volume: 112, Issue:7, 2002
Hypothalamic digoxin and hemispheric chemical dominance--relation to the pathogenesis of senile osteoporosis, degenerative osteoarthritis, and spondylosis.The International journal of neuroscience, , Volume: 113, Issue:3, 2003
[Glycosyltranferases. Biological and pathological importance].Annales de biologie clinique, , Volume: 34, Issue:4, 1976
Familial hypothalamic digoxin deficiency syndrome.The Journal of neuropsychiatry and clinical neurosciences, ,Winter, Volume: 16, Issue:1, 2004
Hypothalamic digoxin and hemispheric chemical dominance--relation to the pathogenesis of senile osteoporosis, degenerative osteoarthritis, and spondylosis.The International journal of neuroscience, , Volume: 113, Issue:3, 2003
Glycosylation defects underlying fetal alcohol spectrum disorder: a novel pathogenetic model. "When the wine goes in, strange things come out" - S.T. Coleridge, The Piccolomini.Journal of inherited metabolic disease, , Volume: 35, Issue:3, 2012
Elevated levels of dolichol in the brains of mucopolysaccharidosis and related disorders.Molecular and chemical neuropathology, , Volume: 22, Issue:2, 1994
Dolichols and proliferating systems.Acta biochimica Polonica, , Volume: 41, Issue:3, 1994
Gamma-glutamyltransferase, aspartate and alanine aminotransferases and their ratio, mean cell volume and urinary dolichol in pregnant alcohol abusers.British journal of obstetrics and gynaecology, , Volume: 99, Issue:4, 1992
Serum dolichols in different clinical conditions.Scandinavian journal of clinical and laboratory investigation, , Volume: 51, Issue:8, 1991
Some aspects of glycosylation in rat liver during pregnancy.Bioscience reports, , Volume: 9, Issue:5, 1989
Significant increases in urinary dolichol levels in bacterial infections, malignancies and pregnancy but not in other clinical conditions.Annals of medicine, , Volume: 21, Issue:1, 1989
Dolichol content and isoprenolog distribution in developing rat small intestine.Pediatric research, , Volume: 21, Issue:3, 1987
The formation of lipid-linked sugars as intermediates in glycoprotein synthesis in rabbit mammary gland.The Biochemical journal, , Feb-15, Volume: 170, Issue:2, 1978
De novo DHDDS variants cause a neurodevelopmental and neurodegenerative disorder with myoclonus.Brain : a journal of neurology, , 03-29, Volume: 145, Issue:1, 2022
Mutation K42E in dehydrodolichol diphosphate synthase (DHDDS) causes recessive retinitis pigmentosa.Advances in experimental medicine and biology, , Volume: 801, 2014
Aberrant dolichol chain lengths as biomarkers for retinitis pigmentosa caused by impaired dolichol biosynthesis.Journal of lipid research, , Volume: 54, Issue:12, 2013
Whole-exome sequencing links a variant in DHDDS to retinitis pigmentosa.American journal of human genetics, , Feb-11, Volume: 88, Issue:2, 2011
Electrospray ionization mass spectrometry analysis of polyisoprenoid alcohols via Li+ cationization.Analytical biochemistry, , Aug-15, Volume: 355, Issue:2, 2006
Application of fluorophore-assisted carbohydrate electrophoresis for the study of the dolichol pyrophosphate-linked oligosaccharides pathway in cell cultures and animal tissues.Methods in molecular biology (Clifton, N.J.), , Volume: 347, 2006
A study of urinary dolichols as a biological marker for alcohol abuse. Report 1: Quantitation of urinary dolichols by high performance liquid chromatography after BondElutC18 (500 mg) cartridge extraction.Arukoru kenkyu to yakubutsu izon = Japanese journal of alcohol studies & drug dependence, , Volume: 29, Issue:3, 1994
The isoprenoid pathway in lone atrial fibrillation with embolic stroke.Indian heart journal, , Volume: 53, Issue:2
[Biomarkers of alcohol abuse. Part II. New biomarkers and their interpretation].Psychiatria polska, , Volume: 44, Issue:1
Glycosylation defects underlying fetal alcohol spectrum disorder: a novel pathogenetic model. "When the wine goes in, strange things come out" - S.T. Coleridge, The Piccolomini.Journal of inherited metabolic disease, , Volume: 35, Issue:3, 2012
Reduced mannose incorporation into GDP-mannose and dolichol-linked intermediates of N-glycosylation in hamster liver during vitamin A deficiency.Molecular and cellular biochemistry, , Mar-27, Volume: 93, Issue:2, 1990
Isolation, characterization, and biological activity of retinyl phosphate from hamster intestinal epithelium.Journal of lipid research, , Volume: 17, Issue:3, 1976
Growth inhibition of leukemia cell line CEM-C1 by farnesol: effects of phosphatidylcholine and diacylglycerol.Biochemical and biophysical research communications, , Jul-15, Volume: 186, Issue:1, 1992
Increased dolichol content in glucocorticoid-sensitive human T-cell leukemia line grown in the presence of dexamethasone.Biochemical and biophysical research communications, , Jan-16, Volume: 158, Issue:1, 1989
Antimalarial drug targets and drugs targeting dolichol metabolic pathway of Plasmodium falciparum.Current drug targets, , Volume: 15, Issue:4, 2014
The methylerythritol phosphate pathway is functionally active in all intraerythrocytic stages of Plasmodium falciparum.The Journal of biological chemistry, , Dec-10, Volume: 279, Issue:50, 2004
Terpenes arrest parasite development and inhibit biosynthesis of isoprenoids in Plasmodium falciparum.Antimicrobial agents and chemotherapy, , Volume: 48, Issue:7, 2004
A new role for dolichol isoform profile in the diagnostics of CDG disorders.Clinica chimica acta; international journal of clinical chemistry, , Volume: 507, 2020
SRD5A3-CDG: Expanding the phenotype of a congenital disorder of glycosylation with emphasis on adult onset features.American journal of medical genetics. Part A, , Volume: 170, Issue:12, 2016
A case of fatal Type I congenital disorders of glycosylation (CDG I) associated with low dehydrodolichol diphosphate synthase (DHDDS) activity.Orphanet journal of rare diseases, , 06-24, Volume: 11, Issue:1, 2016
Genetic defects in dolichol metabolism.Journal of inherited metabolic disease, , Volume: 38, Issue:1, 2015
Approaches to homozygosity mapping and exome sequencing for the identification of novel types of CDG.Glycoconjugate journal, , Volume: 30, Issue:1, 2013
Regulation of dolichol-linked glycosylation.Glycoconjugate journal, , Volume: 30, Issue:1, 2013
Severe, fatal multisystem manifestations in a patient with dolichol kinase-congenital disorder of glycosylation.Molecular genetics and metabolism, , Volume: 110, Issue:4, 2013
Heritable disorders in the metabolism of the dolichols: A bridge from sterol biosynthesis to molecular glycosylation.American journal of medical genetics. Part C, Seminars in medical genetics, , Nov-15, Volume: 160C, Issue:4, 2012
Improved diagnostics lead to identification of three new patients with congenital disorder of glycosylation-Ip.Human mutation, , Volume: 33, Issue:3, 2012
Life with too much polyprenol: polyprenol reductase deficiency.Molecular genetics and metabolism, , Volume: 105, Issue:4, 2012
5-thiomannosides block the biosynthesis of dolichol-linked oligosaccharides and mimic class I congenital disorders of glycosylation.Chembiochem : a European journal of chemical biology, , Feb-13, Volume: 13, Issue:3, 2012
Improvement of dolichol-linked oligosaccharide biosynthesis by the squalene synthase inhibitor zaragozic acid.The Journal of biological chemistry, , Feb-25, Volume: 286, Issue:8, 2011
From glycosylation disorders to dolichol biosynthesis defects: a new class of metabolic diseases.Journal of inherited metabolic disease, , Volume: 34, Issue:4, 2011
Congenital disorders of glycosylation: review of their molecular bases, clinical presentations and specific therapies.European journal of pediatrics, , Volume: 162, Issue:6, 2003
Carbohydrate-deficient glycoprotein syndromes.Acta biochimica Polonica, , Volume: 46, Issue:3, 1999
Glycoproteins and their relationship to human disease.Acta anatomica, , Volume: 161, Issue:1-4, 1998
A novel carbohydrate-deficient glycoprotein syndrome characterized by a deficiency in glucosylation of the dolichol-linked oligosaccharide.The Journal of clinical investigation, , Aug-15, Volume: 102, Issue:4, 1998
A partial deficiency of dehydrodolichol reduction is a cause of carbohydrate-deficient glycoprotein syndrome type I.The Journal of biological chemistry, , Mar-14, Volume: 272, Issue:11, 1997
Abnormal synthesis of dolichol-linked oligosaccharides in carbohydrate-deficient glycoprotein syndrome.Glycobiology, , Volume: 5, Issue:5, 1995
Hepatic isoprenoid metabolism in a rat model of Smith-Lemli-Opitz Syndrome.Lipids, , Volume: 48, Issue:3, 2013
Increased nonsterol isoprenoids, dolichol and ubiquinone, in the Smith-Lemli-Opitz syndrome: effects of dietary cholesterol.Journal of lipid research, , Volume: 47, Issue:12, 2006
A new role for dolichol isoform profile in the diagnostics of CDG disorders.Clinica chimica acta; international journal of clinical chemistry, , Volume: 507, 2020
A case of fatal Type I congenital disorders of glycosylation (CDG I) associated with low dehydrodolichol diphosphate synthase (DHDDS) activity.Orphanet journal of rare diseases, , 06-24, Volume: 11, Issue:1, 2016
SRD5A3-CDG: Expanding the phenotype of a congenital disorder of glycosylation with emphasis on adult onset features.American journal of medical genetics. Part A, , Volume: 170, Issue:12, 2016
Genetic defects in dolichol metabolism.Journal of inherited metabolic disease, , Volume: 38, Issue:1, 2015
Regulation of dolichol-linked glycosylation.Glycoconjugate journal, , Volume: 30, Issue:1, 2013
Approaches to homozygosity mapping and exome sequencing for the identification of novel types of CDG.Glycoconjugate journal, , Volume: 30, Issue:1, 2013
Severe, fatal multisystem manifestations in a patient with dolichol kinase-congenital disorder of glycosylation.Molecular genetics and metabolism, , Volume: 110, Issue:4, 2013
Heritable disorders in the metabolism of the dolichols: A bridge from sterol biosynthesis to molecular glycosylation.American journal of medical genetics. Part C, Seminars in medical genetics, , Nov-15, Volume: 160C, Issue:4, 2012
Improved diagnostics lead to identification of three new patients with congenital disorder of glycosylation-Ip.Human mutation, , Volume: 33, Issue:3, 2012
5-thiomannosides block the biosynthesis of dolichol-linked oligosaccharides and mimic class I congenital disorders of glycosylation.Chembiochem : a European journal of chemical biology, , Feb-13, Volume: 13, Issue:3, 2012
Life with too much polyprenol: polyprenol reductase deficiency.Molecular genetics and metabolism, , Volume: 105, Issue:4, 2012
Improvement of dolichol-linked oligosaccharide biosynthesis by the squalene synthase inhibitor zaragozic acid.The Journal of biological chemistry, , Feb-25, Volume: 286, Issue:8, 2011
From glycosylation disorders to dolichol biosynthesis defects: a new class of metabolic diseases.Journal of inherited metabolic disease, , Volume: 34, Issue:4, 2011
Congenital disorders of glycosylation: review of their molecular bases, clinical presentations and specific therapies.European journal of pediatrics, , Volume: 162, Issue:6, 2003
Carbohydrate-deficient glycoprotein syndromes.Acta biochimica Polonica, , Volume: 46, Issue:3, 1999
A novel carbohydrate-deficient glycoprotein syndrome characterized by a deficiency in glucosylation of the dolichol-linked oligosaccharide.The Journal of clinical investigation, , Aug-15, Volume: 102, Issue:4, 1998
Glycoproteins and their relationship to human disease.Acta anatomica, , Volume: 161, Issue:1-4, 1998
A partial deficiency of dehydrodolichol reduction is a cause of carbohydrate-deficient glycoprotein syndrome type I.The Journal of biological chemistry, , Mar-14, Volume: 272, Issue:11, 1997
Abnormal synthesis of dolichol-linked oligosaccharides in carbohydrate-deficient glycoprotein syndrome.Glycobiology, , Volume: 5, Issue:5, 1995
Hepatic isoprenoid metabolism in a rat model of Smith-Lemli-Opitz Syndrome.Lipids, , Volume: 48, Issue:3, 2013
Increased nonsterol isoprenoids, dolichol and ubiquinone, in the Smith-Lemli-Opitz syndrome: effects of dietary cholesterol.Journal of lipid research, , Volume: 47, Issue:12, 2006
Glycosylation defects underlying fetal alcohol spectrum disorder: a novel pathogenetic model. "When the wine goes in, strange things come out" - S.T. Coleridge, The Piccolomini.Journal of inherited metabolic disease, , Volume: 35, Issue:3, 2012
Gamma-glutamyltransferase, aspartate and alanine aminotransferases and their ratio, mean cell volume and urinary dolichol in pregnant alcohol abusers.British journal of obstetrics and gynaecology, , Volume: 99, Issue:4, 1992
Glycosylation defects underlying fetal alcohol spectrum disorder: a novel pathogenetic model. "When the wine goes in, strange things come out" - S.T. Coleridge, The Piccolomini.Journal of inherited metabolic disease, , Volume: 35, Issue:3, 2012
Hypothalamic digoxin and isoprenoid pathway dysfunction relation to alcoholic addiction, alcoholic cirrhosis, and acquired hepatocerebral degeneration--relation to hemispheric chemical dominance.The International journal of neuroscience, , Volume: 113, Issue:4, 2003
Effect of chronic ethanol consumption on glycosylation processes in rat liver microsomes and Golgi apparatus.Alcohol and alcoholism (Oxford, Oxfordshire), , Volume: 31, Issue:1, 1996
A study of urinary dolichols as a biological marker for alcohol abuse. Report 1: Quantitation of urinary dolichols by high performance liquid chromatography after BondElutC18 (500 mg) cartridge extraction.Arukoru kenkyu to yakubutsu izon = Japanese journal of alcohol studies & drug dependence, , Volume: 29, Issue:3, 1994
A study of urinary dolichols as a biological marker for alcohol abuse. Report 2: Comparison of urinary dolichols/creatinine concentrations among non-drinkers, moderate-drinkers and heavy-drinkers.Arukoru kenkyu to yakubutsu izon = Japanese journal of alcohol studies & drug dependence, , Volume: 29, Issue:5, 1994
Effect of alcohol on urinary and blood dolichols.Biochemistry and cell biology = Biochimie et biologie cellulaire, , Volume: 70, Issue:6, 1992
Gamma-glutamyltransferase, aspartate and alanine aminotransferases and their ratio, mean cell volume and urinary dolichol in pregnant alcohol abusers.British journal of obstetrics and gynaecology, , Volume: 99, Issue:4, 1992
Urinary dolichol--a doubtful marker of alcoholism.Alcoholism, clinical and experimental research, , Volume: 15, Issue:6, 1991
Brain and liver dolichol in chronic alcoholism: a necropsy study.Alcoholism, clinical and experimental research, , Volume: 14, Issue:4, 1990
Effect of alcohol on blood dolichol concentration.Alcoholism, clinical and experimental research, , Volume: 13, Issue:4, 1989
Urinary dolichol--a new marker of alcoholism.Alcoholism, clinical and experimental research, , Volume: 11, Issue:6, 1987
Blood acetate and urinary dolichols--new markers of heavy drinking and alcoholism.Progress in clinical and biological research, , Volume: 241, 1987
Liquid-chromatographic determination of dolichols in urine.Clinical chemistry, , Volume: 32, Issue:11, 1986
[Biomarkers of alcohol abuse. Part II. New biomarkers and their interpretation].Psychiatria polska, , Volume: 44, Issue:1
Elevated urinary dolichol levels in chronic alcoholics.Alcoholism, clinical and experimental research, , Volume: 9, Issue:1
Hypothalamic digoxin, hemispheric chemical dominance, and Alzheimer's disease.The International journal of neuroscience, , Volume: 113, Issue:3, 2003
Isoprenoids in aging and neurodegeneration.Neurochemistry international, , Volume: 25, Issue:1, 1994
Lipid composition in different regions of the brain in Alzheimer's disease/senile dementia of Alzheimer's type.Journal of neurochemistry, , Volume: 59, Issue:5, 1992
Protease inhibition causes some manifestations of aging and Alzheimer's disease in rodent and primate brain.Annals of the New York Academy of Sciences, , Dec-31, Volume: 674, 1992
Ubiquinone, dolichol, and cholesterol metabolism in aging and Alzheimer's disease.Biochemistry and cell biology = Biochimie et biologie cellulaire, , Volume: 70, Issue:6, 1992
Lipid abnormalities in the brain in adult Down's syndrome and Alzheimer's disease.Molecular and chemical neuropathology, , Volume: 11, Issue:3, 1989
Dolichol and dolichyl phosphate in the neuronal ceroid-lipofuscinoses and other diseases.American journal of medical genetics. Supplement, , Volume: 5, 1988
Dolichols are elevated in brain tissue from Alzheimer's disease, but not in urinary sediment from Alzheimer's disease and Down's syndrome.Neurochemical pathology, ,Winter, Volume: 3, Issue:4, 1985
High levels of brain dolichols in neuronal ceroid-lipofuscinosis and senescence.Journal of neurochemistry, , Volume: 40, Issue:5, 1983
Raised levels of cerebral cortex dolichols in Alzheimer's disease.Lancet (London, England), , Jul-10, Volume: 2, Issue:8289, 1982
Isoprenoid pathway-related membrane dysfunction in neuropsychiatric disorders.The International journal of neuroscience, , Volume: 113, Issue:11, 2003
Hypothalamic digoxin, hemispheric dominance, and neuroimmune integration.The International journal of neuroscience, , Volume: 112, Issue:4, 2002
Effects of vitamin E on dolichol content of rats acutely treated with 1,2-dichloroethane.Toxicology, , Mar-07, Volume: 143, Issue:3, 2000
Effects of aging and diet on the accumulation of dolichol in rat tissues.Biochemistry and cell biology = Biochimie et biologie cellulaire, , Volume: 74, Issue:2, 1996
Effects of casein and soy protein on accumulation of cholesterol and dolichol in rat liver.Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N.Y.), , Volume: 203, Issue:1, 1993
Changes in murine tissue concentrations of dolichol and dolichol derivatives associated with age.Lipids, , Volume: 25, Issue:10, 1990
Effects of lovastatin and leupeptin on ceroidogenesis of vitamin E-deficient and -supplemented young rats.Advances in experimental medicine and biology, , Volume: 266, 1989
Quantitation of excretion of dolichol and dolichyl phosphate from the rat.Bioscience reports, , Volume: 4, Issue:9, 1984
Approaches to homozygosity mapping and exome sequencing for the identification of novel types of CDG.Glycoconjugate journal, , Volume: 30, Issue:1, 2013
New form of glycosylation disorder identified.American journal of medical genetics. Part A, , Volume: 152A, Issue:10, 2010
Quality control of glycoproteins bearing truncated glycans in an ALG9-defective (CDG-IL) patient.Glycobiology, , Volume: 19, Issue:8, 2009
Congenital disorders of glycosylation: an update on defects affecting the biosynthesis of dolichol-linked oligosaccharides.Human mutation, , Volume: 30, Issue:12, 2009
Improvement of CDG diagnosis by combined examination of several glycoproteins.Journal of inherited metabolic disease, , Volume: 27, Issue:5, 2004
A new type of congenital disorders of glycosylation (CDG-Ii) provides new insights into the early steps of dolichol-linked oligosaccharide biosynthesis.The Journal of biological chemistry, , Jun-20, Volume: 278, Issue:25, 2003
Research advances on neurite outgrowth inhibitor B receptor.Journal of cellular and molecular medicine, , Volume: 24, Issue:14, 2020
Effect of virus-transformation and growth factor stimulation on isoprene biosynthesis in human fibroblasts: a correlation to cell growth.Cancer biochemistry biophysics, , Volume: 14, Issue:4, 1995
Dolichols and enzymatic formation of dolichyl phosphate sugars in the thymus of mice on neoplastic transformation.Acta biochimica Polonica, , Volume: 32, Issue:1, 1985
Lipid intermediates in glycosylation reactions in preneoplastic nodules of the liver.Acta chemica Scandinavica. Series B: Organic chemistry and biochemistry, , Volume: 36, Issue:8, 1982
Glucuronosyl-N-acetylglucosaminyl pyrophosphoryldolichol. Formation in SV40-transformed human lung fibroblasts and biosynthesis in rat lung microsomal preparations.The Journal of biological chemistry, , May-10, Volume: 252, Issue:9, 1977
Effect of virus-transformation and growth factor stimulation on isoprene biosynthesis in human fibroblasts: a correlation to cell growth.Cancer biochemistry biophysics, , Volume: 14, Issue:4, 1995
Abolition of mevinolin-induced growth inhibition in human fibroblasts following transformation by simian virus 40.Cancer research, , Oct-15, Volume: 49, Issue:20, 1989
Mevalonic acid products as mediators of cell proliferation in simian virus 40-transformed 3T3 cells.Cancer research, , Sep-15, Volume: 47, Issue:18, 1987
High levels of brain dolichols in neuronal ceroid-lipofuscinosis and senescence.Journal of neurochemistry, , Volume: 40, Issue:5, 1983
Raised levels of cerebral cortex dolichols in Alzheimer's disease.Lancet (London, England), , Jul-10, Volume: 2, Issue:8289, 1982
Hepatic isoprenoid metabolism in a rat model of Smith-Lemli-Opitz Syndrome.Lipids, , Volume: 48, Issue:3, 2013
5-thiomannosides block the biosynthesis of dolichol-linked oligosaccharides and mimic class I congenital disorders of glycosylation.Chembiochem : a European journal of chemical biology, , Feb-13, Volume: 13, Issue:3, 2012
Deletion of a single mevalonate kinase (Mvk) allele yields a murine model of hyper-IgD syndrome.Journal of inherited metabolic disease, , Volume: 30, Issue:6, 2007
Changed cellular membrane lipid composition and lipid peroxidation of kidney in rats with chronic fluorosis.Archives of toxicology, , Volume: 74, Issue:10, 2000
Alterations in the biosynthesis of cholesterol, dolichol and dolichyl-P in the genetic cholesterol homeostasis disorder, Niemann-Pick type C disease.Biochimica et biophysica acta, , Nov-02, Volume: 1394, Issue:2-3, 1998
Adult type of neuronal ceroid lipofuscinosis.Developmental neuroscience, , Volume: 13, Issue:4-5, 1991
Animal model: ceroidosis (ceroid-lipofuscinosis) in Australian cattle dogs.American journal of medical genetics, , Volume: 26, Issue:4, 1987
Ceroid lipofuscinosis in sheep. I. Bis(monoacylglycero)phosphate, dolichol, ubiquinone, phospholipids, fatty acids, and fluorescence in liver lipopigment lipids.The Journal of biological chemistry, , Feb-05, Volume: 261, Issue:4, 1986
Ceroid lipofuscinosis in sheep. II. The major component of the lipopigment in liver, kidney, pancreas, and brain is low molecular weight protein.The Journal of biological chemistry, , Feb-05, Volume: 261, Issue:4, 1986
Research advances on neurite outgrowth inhibitor B receptor.Journal of cellular and molecular medicine, , Volume: 24, Issue:14, 2020
Endogenous hypodigoxinemia-related immune deficiency syndrome.The International journal of neuroscience, , Volume: 113, Issue:9, 2003
Hypothalamic digoxin and isoprenoid pathway dysfunction relation to alcoholic addiction, alcoholic cirrhosis, and acquired hepatocerebral degeneration--relation to hemispheric chemical dominance.The International journal of neuroscience, , Volume: 113, Issue:4, 2003
Adult type of neuronal ceroid lipofuscinosis.Developmental neuroscience, , Volume: 13, Issue:4-5, 1991
Animal model: ceroidosis (ceroid-lipofuscinosis) in Australian cattle dogs.American journal of medical genetics, , Volume: 26, Issue:4, 1987
Dolichol and dolichyl phosphate levels in brain tissue from English setters with ceroid lipofuscinosis.Journal of neurochemistry, , Volume: 42, Issue:4, 1984
Lipid abnormalities in the brain in adult Down's syndrome and Alzheimer's disease.Molecular and chemical neuropathology, , Volume: 11, Issue:3, 1989
Dolichols are elevated in brain tissue from Alzheimer's disease, but not in urinary sediment from Alzheimer's disease and Down's syndrome.Neurochemical pathology, ,Winter, Volume: 3, Issue:4, 1985
Hypothalamic digoxin-mediated model for trisomy 21.Pediatric pathology & molecular medicine, , Volume: 22, Issue:5
Effect of chronic ethanol consumption on glycosylation processes in rat liver microsomes and Golgi apparatus.Alcohol and alcoholism (Oxford, Oxfordshire), , Volume: 31, Issue:1, 1996
[Changes in lipoglycoprotein metabolism in toxic fatty liver].Minerva gastroenterologica e dietologica, , Volume: 39, Issue:3, 1993
Brain and liver dolichol in chronic alcoholism: a necropsy study.Alcoholism, clinical and experimental research, , Volume: 14, Issue:4, 1990
Dolichol biosynthesis in human malignant cells.The Biochemical journal, , Sep-15, Volume: 278 ( Pt 3), 1991
Modulation of metabolism in HepG2 cells upon treatment with cyclosporin A and Nva2-cyclosporin.Experimental and molecular pathology, , Volume: 54, Issue:3, 1991
Studies on the polyisoprenoid composition in hepatocellular carcinomas and its correlation with their differentiation.APMIS : acta pathologica, microbiologica, et immunologica Scandinavica, , Volume: 98, Issue:6, 1990
Studies on the biosynthesis of polyisoprenols, cholesterol and ubiquinone in highly differentiated human hepatomas.Journal of experimental pathology (Oxford, England), , Volume: 71, Issue:2, 1990
Polyisoprenoid, cholesterol and ubiquinone levels in human hepatocellular carcinomas.British journal of experimental pathology, , Volume: 70, Issue:1, 1989
The lipid composition of highly differentiated human hepatomas, with special reference to fatty acids.British journal of experimental pathology, , Volume: 69, Issue:5, 1988
Cytidine 5'-triphosphate-dependent dolichol kinase and dolichol phosphatase activities and levels of dolichyl phosphate in microsomal fractions from highly differentiated human hepatomas.Cancer research, , Jun-15, Volume: 48, Issue:12, 1988
Biosynthesis of sterols and dolichol in human hepatomas.Acta chemica Scandinavica. Series B: Organic chemistry and biochemistry, , Volume: 41, Issue:1, 1987
Polyprenol content in primary human liver carcinoma.Acta chemica Scandinavica. Series B: Organic chemistry and biochemistry, , Volume: 39, Issue:4, 1985
Hypothalamic-mediated model for Creutzfeldt-Jakob disease: relation to hemispheric chemical dominance.The International journal of neuroscience, , Volume: 113, Issue:7, 2003
Hypothalamic digoxin, hemispheric dominance, and neuroimmune integration.The International journal of neuroscience, , Volume: 112, Issue:4, 2002
Hypothalamic digoxin and isoprenoid pathway dysfunction relation to alcoholic addiction, alcoholic cirrhosis, and acquired hepatocerebral degeneration--relation to hemispheric chemical dominance.The International journal of neuroscience, , Volume: 113, Issue:4, 2003
Brain and liver dolichol in chronic alcoholism: a necropsy study.Alcoholism, clinical and experimental research, , Volume: 14, Issue:4, 1990
Regulation of ubiquinone metabolism.Free radical biology & medicine, , Volume: 29, Issue:3-4, 2000
Evidence for protein dolichylation.FEBS letters, , Oct-27, Volume: 416, Issue:3, 1997
Enzymes of the mevalonate pathway in rat liver nodules induced by 2-acetylaminofluorene treatment.Carcinogenesis, , Volume: 16, Issue:3, 1995
Dolichol biosynthesis in human malignant cells.The Biochemical journal, , Sep-15, Volume: 278 ( Pt 3), 1991
Modulation of metabolism in HepG2 cells upon treatment with cyclosporin A and Nva2-cyclosporin.Experimental and molecular pathology, , Volume: 54, Issue:3, 1991
Studies on the polyisoprenoid composition in hepatocellular carcinomas and its correlation with their differentiation.APMIS : acta pathologica, microbiologica, et immunologica Scandinavica, , Volume: 98, Issue:6, 1990
Studies on the biosynthesis of polyisoprenols, cholesterol and ubiquinone in highly differentiated human hepatomas.Journal of experimental pathology (Oxford, England), , Volume: 71, Issue:2, 1990
Polyisoprenoid, cholesterol and ubiquinone levels in human hepatocellular carcinomas.British journal of experimental pathology, , Volume: 70, Issue:1, 1989
The lipid composition of highly differentiated human hepatomas, with special reference to fatty acids.British journal of experimental pathology, , Volume: 69, Issue:5, 1988
Cytidine 5'-triphosphate-dependent dolichol kinase and dolichol phosphatase activities and levels of dolichyl phosphate in microsomal fractions from highly differentiated human hepatomas.Cancer research, , Jun-15, Volume: 48, Issue:12, 1988
Biosynthesis of sterols and dolichol in human hepatomas.Acta chemica Scandinavica. Series B: Organic chemistry and biochemistry, , Volume: 41, Issue:1, 1987
Polyprenol content in primary human liver carcinoma.Acta chemica Scandinavica. Series B: Organic chemistry and biochemistry, , Volume: 39, Issue:4, 1985
Role of dolichyl phosphate in regulation of protein glycosylation in 2-acetylaminofluorene-induced carcinogenesis in rat liver.Cancer research, , Volume: 44, Issue:2, 1984
Lipid intermediates in glycosylation reactions in preneoplastic nodules of the liver.Acta chemica Scandinavica. Series B: Organic chemistry and biochemistry, , Volume: 36, Issue:8, 1982
Lipid compositions of intracellular membranes isolated from rat liver nodules in Wistar rats.Cancer research, , Jul-15, Volume: 51, Issue:14, 1991
Effects of simvastatin (MK-733) on branched pathway of mevalonate.Japanese journal of pharmacology, , Volume: 54, Issue:3, 1990
Time course of dolichol and dolichyl phosphate during chemical carcinogenesis in rat liver.Biochimica et biophysica acta, , Oct-17, Volume: 921, Issue:3, 1987
Effects of dibutyryl cyclic AMP on the syntheses of dolichol-linked saccharides and glycoproteins in cultured hepatoma cells. Correlation with the effect on the adhesiveness of the cells.The Biochemical journal, , Jun-15, Volume: 212, Issue:3, 1983
Hypothalamic digoxin, hemispheric chemical dominance, and sarcoidosis.The International journal of neuroscience, , Volume: 113, Issue:11, 2003
Hypothalamic digoxin, hemispheric chemical dominance, and interstitial lung disease.The International journal of neuroscience, , Volume: 113, Issue:10, 2003
Hypothalamic digoxin, cerebral chemical dominance, and pathogenesis of pulmonary diseases.The International journal of neuroscience, , Volume: 113, Issue:2, 2003
Significant increases in urinary dolichol levels in bacterial infections, malignancies and pregnancy but not in other clinical conditions.Annals of medicine, , Volume: 21, Issue:1, 1989
The phenotype of five classes of T lymphoma mutants. Defective glycophospholipid anchoring, rapid degradation, and secretion of Thy-1 glycoprotein.The Journal of biological chemistry, , Jan-25, Volume: 263, Issue:3, 1988
Mutation of Nogo-B receptor, a subunit of cis-prenyltransferase, causes a congenital disorder of glycosylation.Cell metabolism, , Sep-02, Volume: 20, Issue:3, 2014
From glycosylation disorders to dolichol biosynthesis defects: a new class of metabolic diseases.Journal of inherited metabolic disease, , Volume: 34, Issue:4, 2011
Decreased plasma ubiquinone-10 concentration in patients with mevalonate kinase deficiency.Pediatric research, , Volume: 34, Issue:2, 1993
Elevated levels of serum dolichol in aspartylglucosaminuria.Life sciences, , Volume: 47, Issue:7, 1990
Elevated urinary dolichol excretion in the Hermansky-Pudlak syndrome. Indicator of lysosomal dysfunction.The American journal of medicine, , Volume: 82, Issue:3, 1987
Isoprenoid pathway related cascade in multiple myeloma.Pathology oncology research : POR, , Volume: 9, Issue:2, 2003
Hypothalamic digoxin, hemispheric chemical dominance, and oncogenesis: evidence from multiple myeloma.The International journal of neuroscience, , Volume: 113, Issue:12, 2003
In vitro and in vivo downregulation of the ATP binding cassette transporter B1 by the HMG-CoA reductase inhibitor simvastatin.Naunyn-Schmiedeberg's archives of pharmacology, , Volume: 389, Issue:1, 2016
Suppression of dolichol synthesis with isoprenoids and statins may potentiate the cancer-retardant efficacy of IGF-I down-regulation.Medical hypotheses, , Volume: 56, Issue:1, 2001
Glycoproteins and their relationship to human disease.Acta anatomica, , Volume: 161, Issue:1-4, 1998
Serum dolichols in different clinical conditions.Scandinavian journal of clinical and laboratory investigation, , Volume: 51, Issue:8, 1991
Significant increases in urinary dolichol levels in bacterial infections, malignancies and pregnancy but not in other clinical conditions.Annals of medicine, , Volume: 21, Issue:1, 1989
Schizoid neurochemical pathology-induced membrane Na(+)-K+ ATPase inhibition in relation to neurological disorders.The International journal of neuroscience, , Volume: 113, Issue:12, 2003
Isoprenoid pathway-related membrane dysfunction in neuropsychiatric disorders.The International journal of neuroscience, , Volume: 113, Issue:11, 2003
Urinary sediment dolichols in the diagnosis of neuronal ceroid-lipofuscinosis.Annals of neurology, , Volume: 19, Issue:3, 1986
Urinary sediment dolichol excretion in patients with Batten disease and other neurodegenerative and storage disorders.Pediatric research, , Volume: 19, Issue:2, 1985
Blood dolichol in lysosomal diseases.Biochemistry and cell biology = Biochimie et biologie cellulaire, , Volume: 70, Issue:6, 1992
Perspective of biochemical research in the neuronal ceroid-lipofuscinosis.American journal of medical genetics, , Feb-15, Volume: 42, Issue:4, 1992
Rett syndrome and metabolic disorder.Journal of the American Academy of Child and Adolescent Psychiatry, , Volume: 31, Issue:3, 1992
Dolichyl-pyrophosphoryloligosaccharide protein oligosaccharide transferase in neuronal ceroid-lipofuscinosis.Biochemistry and cell biology = Biochimie et biologie cellulaire, , Volume: 70, Issue:6, 1992
Adult type of neuronal ceroid lipofuscinosis.Developmental neuroscience, , Volume: 13, Issue:4-5, 1991
Low molecular weight urinary peptides in ceroid-lipofuscinoses: potential biochemical markers for the juvenile subtype.American journal of medical genetics, , Volume: 37, Issue:4, 1990
High-mannose dolichol-linked oligosaccharides in infantile ceroid-lipofuscinosis.Biochemical Society transactions, , Volume: 17, Issue:6, 1989
Analysis of dolichyl pyrophosphoryl oligosaccharides in purified storage cytosomes from ovine ceroid-lipofuscinosis.Biochimica et biophysica acta, , Dec-08, Volume: 993, Issue:2-3, 1989
Clinical and biochemical studies of Japanese neuronal ceroid-lipofuscinosis.American journal of medical genetics. Supplement, , Volume: 5, 1988
Ceroid-lipofuscinosis. Report of two autopsy cases.Acta pathologica japonica, , Volume: 38, Issue:9, 1988
Dolichol and dolichyl phosphate in the neuronal ceroid-lipofuscinoses and other diseases.American journal of medical genetics. Supplement, , Volume: 5, 1988
Animal model: ceroidosis (ceroid-lipofuscinosis) in Australian cattle dogs.American journal of medical genetics, , Volume: 26, Issue:4, 1987
Normal dolichol concentration in urine sediments from four patients with neuronal ceroid lipofuscinosis (Batten's disease).Journal of inherited metabolic disease, , Volume: 10, Issue:1, 1987
Accumulation of phosphorylated dolichol in several tissues in ceroid-lipofuscinosis (Batten disease).Clinica chimica acta; international journal of clinical chemistry, , Volume: 170, Issue:2-3, 1987
Urinary sediment dolichols in the diagnosis of neuronal ceroid-lipofuscinosis.Annals of neurology, , Volume: 19, Issue:3, 1986
Ceroid lipofuscinosis in sheep. II. The major component of the lipopigment in liver, kidney, pancreas, and brain is low molecular weight protein.The Journal of biological chemistry, , Feb-05, Volume: 261, Issue:4, 1986
Ceroid lipofuscinosis in sheep. I. Bis(monoacylglycero)phosphate, dolichol, ubiquinone, phospholipids, fatty acids, and fluorescence in liver lipopigment lipids.The Journal of biological chemistry, , Feb-05, Volume: 261, Issue:4, 1986
Abnormal excretion of autofluorescent lipids in urine from patients with neuronal ceroid lipofuscinosis.The Tohoku journal of experimental medicine, , Volume: 148, Issue:4, 1986
Dolichol and phosphorylated dolichol content of tissues in ceroid-lipofuscinosis.Journal of inherited metabolic disease, , Volume: 8, Issue:4, 1985
Urinary sediment dolichol excretion in patients with Batten disease and other neurodegenerative and storage disorders.Pediatric research, , Volume: 19, Issue:2, 1985
Dolichol and dolichyl phosphate levels in brain tissue from English setters with ceroid lipofuscinosis.Journal of neurochemistry, , Volume: 42, Issue:4, 1984
Dolichol metabolism in cultured skin fibroblasts from patients with "neuronal" ceroid lipofuscinosis (Batten's disease).Journal of inherited metabolic disease, , Volume: 7, Issue:3, 1984
Dolichols in brain and urinary sediment in neuronal ceroid lipofuscinosis.Neurology, , Volume: 33, Issue:1, 1983
High levels of brain dolichols in neuronal ceroid-lipofuscinosis and senescence.Journal of neurochemistry, , Volume: 40, Issue:5, 1983
Batten disease: new research findings on the biochemical defect.Birth defects original article series, , Volume: 18, Issue:6, 1982
Alterations in the biosynthesis of cholesterol, dolichol and dolichyl-P in the genetic cholesterol homeostasis disorder, Niemann-Pick type C disease.Biochimica et biophysica acta, , Nov-02, Volume: 1394, Issue:2-3, 1998
Changes in the levels of dolichol and dolichyl phosphate in a murine model of Niemann-Pick's type C disease.Journal of neurochemistry, , Volume: 65, Issue:2, 1995
Familial hypothalamic digoxin deficiency syndrome.The Journal of neuropsychiatry and clinical neurosciences, ,Winter, Volume: 16, Issue:1, 2004
Hypothalamic digoxin deficiency in obsessive compulsive disorder and la Tourette's syndrome.The International journal of neuroscience, , Volume: 112, Issue:7, 2002
Familial hypodigoxinemic membrane Na(+)-K(+) ATPase upregulatory syndrome - relation between digoxin status and cerebral dominance.Neurology India, , Volume: 50, Issue:3, 2002
Hypothalamic digoxin and hemispheric chemical dominance--relation to the pathogenesis of senile osteoporosis, degenerative osteoarthritis, and spondylosis.The International journal of neuroscience, , Volume: 113, Issue:3, 2003
[Glycosyltranferases. Biological and pathological importance].Annales de biologie clinique, , Volume: 34, Issue:4, 1976
Familial hypothalamic digoxin deficiency syndrome.The Journal of neuropsychiatry and clinical neurosciences, ,Winter, Volume: 16, Issue:1, 2004
Hypothalamic digoxin and hemispheric chemical dominance--relation to the pathogenesis of senile osteoporosis, degenerative osteoarthritis, and spondylosis.The International journal of neuroscience, , Volume: 113, Issue:3, 2003
Endogenous hypodigoxinemia-related immune deficiency syndrome.The International journal of neuroscience, , Volume: 113, Issue:9, 2003
Hypothalamic digoxin, hemispheric dominance, and neuroimmune integration.The International journal of neuroscience, , Volume: 112, Issue:4, 2002
De novo DHDDS variants cause a neurodevelopmental and neurodegenerative disorder with myoclonus.Brain : a journal of neurology, , 03-29, Volume: 145, Issue:1, 2022
Mutation K42E in dehydrodolichol diphosphate synthase (DHDDS) causes recessive retinitis pigmentosa.Advances in experimental medicine and biology, , Volume: 801, 2014
Aberrant dolichol chain lengths as biomarkers for retinitis pigmentosa caused by impaired dolichol biosynthesis.Journal of lipid research, , Volume: 54, Issue:12, 2013
Whole-exome sequencing links a variant in DHDDS to retinitis pigmentosa.American journal of human genetics, , Feb-11, Volume: 88, Issue:2, 2011
Ceroid lipofuscinosis in sheep. I. Bis(monoacylglycero)phosphate, dolichol, ubiquinone, phospholipids, fatty acids, and fluorescence in liver lipopigment lipids.The Journal of biological chemistry, , Feb-05, Volume: 261, Issue:4, 1986
Ceroid lipofuscinosis in sheep. II. The major component of the lipopigment in liver, kidney, pancreas, and brain is low molecular weight protein.The Journal of biological chemistry, , Feb-05, Volume: 261, Issue:4, 1986
Hypothalamic digoxin-mediated model for subacute sclerosing panencephalitis.Journal of neurovirology, , Volume: 8, Issue:4, 2002
Hypothalamic digoxin, hemispheric dominance, and neuroimmune integration.The International journal of neuroscience, , Volume: 112, Issue:4, 2002
Glycosylation defects underlying fetal alcohol spectrum disorder: a novel pathogenetic model. "When the wine goes in, strange things come out" - S.T. Coleridge, The Piccolomini.Journal of inherited metabolic disease, , Volume: 35, Issue:3, 2012
Reduced mannose incorporation into GDP-mannose and dolichol-linked intermediates of N-glycosylation in hamster liver during vitamin A deficiency.Molecular and cellular biochemistry, , Mar-27, Volume: 93, Issue:2, 1990
Isolation, characterization, and biological activity of retinyl phosphate from hamster intestinal epithelium.Journal of lipid research, , Volume: 17, Issue:3, 1976
Growth inhibition of leukemia cell line CEM-C1 by farnesol: effects of phosphatidylcholine and diacylglycerol.Biochemical and biophysical research communications, , Jul-15, Volume: 186, Issue:1, 1992
Increased dolichol content in glucocorticoid-sensitive human T-cell leukemia line grown in the presence of dexamethasone.Biochemical and biophysical research communications, , Jan-16, Volume: 158, Issue:1, 1989
Antimalarial drug targets and drugs targeting dolichol metabolic pathway of Plasmodium falciparum.Current drug targets, , Volume: 15, Issue:4, 2014
Terpenes arrest parasite development and inhibit biosynthesis of isoprenoids in Plasmodium falciparum.Antimicrobial agents and chemotherapy, , Volume: 48, Issue:7, 2004
The methylerythritol phosphate pathway is functionally active in all intraerythrocytic stages of Plasmodium falciparum.The Journal of biological chemistry, , Dec-10, Volume: 279, Issue:50, 2004
Safety/Toxicity (2)
Long-term Use (1)
Pharmacokinetics (1)
Dosage (7)
| Article | Year |
|---|
Cardioprotection by farnesol: role of the mevalonate pathway.
Cardiovascular drugs and therapy, , Volume: 27, Issue:4 | 2013 |
Chronic high doses of thioacetamide followed by vitamin A modify dolichol, dolichol isoprenoids, and retinol content in rat liver cells.
Drug and chemical toxicology, , Volume: 28, Issue:1 | 2005 |
Association of thioacetamide and ethanol treatment: dolichol and retinol in isolated rat liver cells.
Drug and chemical toxicology, , Volume: 27, Issue:1 | 2004 |
Dolichol content in isolated sinusoidal liver cells after in vivo chronic treatment with thioacetamide.
Experimental and toxicologic pathology : official journal of the Gesellschaft fur Toxikologische Pathologie, , Volume: 54, Issue:1 | 2002 |
Thioacetamide impairs retinol storage and dolichol content in rat liver cells in vivo.
Biochimica et biophysica acta, , Aug-08, Volume: 1583, Issue:3 | 2002 |
Lipophilic 1,1-bisphosphonates are potent squalene synthase inhibitors and orally active cholesterol lowering agents in vivo.
The Journal of biological chemistry, , Nov-25, Volume: 268, Issue:33 | 1993 |
Intestinal absorption of dolichol from emulsions and liposomes in rats.
Chemical & pharmaceutical bulletin, , Volume: 37, Issue:2 | 1989 |